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1. Androgens 
Androgens belong to a group of chemically related male sex hormones that are 
derived from cholesterol. They are required for the normal development of the penis, 
scrotum, testicles and the secondary characteristics of the male body as well as for the 
growth and development of prostate. In addition, androgens are implicated in the 
initiation and progression of prostate cancer.  
Androgens are produced by the Leydig cells in the testis (90%) and by the adrenal 
cortex, a small gland located above the kidney. Testosterone (TST), of which more 
than 95% is secreted from the testis, is the major circulating androgen in men. The 
adrenal cortex and the testis also secrete other androgens, mainly dehydro-
epiandrosterone (DHEA), DHEA sulphate (DHEA-S) and androstenedione. These 
hormones have only weak androgenic activity but they are important substrates for 
extragonadal synthesis of sex steroids (Labrie et al., 2001; Riggs et al., 2002). 
Secretion of testosterone is regulated by the hypothalamic-pituitary-testicular axis. 
The hypothalamus secretes locally acting luteinizing hormone-releasing hormone 
(LHRH), also known as gonadotropin-releasing hormone (GnRH), and 
corticotrophin-releasing hormone (CRH), that act on the pituitary gland. In response 
to these hormones, pituitary secretes luteinizing hormone (LH), follicle stimulating 
hormone (FSH) and adrenocorticotrophin (ACTH) that enter the circulation and 
affect the testis and adrenal glands. While LH acts on the Leydig cells to stimulate 
production of testosterone, ACTH stimulates production of adrenal androgens that are 
converted into testosterone. When testosterone levels in the bloodstream rise, the 
hypothalamus reduces the secretion of LHRH, which inhibits the secretion of LH 
from the pituitary gland and further reduces testosterone secretion. Thus, testosterone 
controls its own release through a negative feedback on the hypothalamic-pituitary-
testicular axis. 
   GENERAL INTRODUCTION 
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In the bloodstream, testosterone circulates bound to one of two proteins, either sex 
hormone binding globulin (SHBG) or albumin. A small percentage of testosterone, 
approximately 2%, remains in a free, unbound form. While free testosterone and 
testosterone dissociated from albumin can enter the cell passively by diffusion, 
SHGB bound testosterone is transported into the cell actively through the membrane 
receptor (Rosner et al., 1999) (see Figure 3). In certain tissues, including the prostate, 
testosterone functions as a prohormone, where it is irreversibly converted to 
dihydrotestosterone (DHT) by the enzyme 5α-reductase. The biological functions of 
androgens are mediated through the androgen receptor (AR). This protein binds both 
testosterone and DHT, although it has a much higher affinity for the latter. In contrast 
to testosterone, DHT dissociates more slowly from AR and its binding induces a 
change in receptor conformation that is more resistant to degradation (Heinlein and 
Chang, 2004). 
 
2. The Androgen Receptor 
AR belongs to a superfamily of proteins that are referred to as nuclear receptors 
(NRs). This superfamily of structurally conserved, ligand-dependent transcription 
factors comprises more than 150 members that most likely evolved from a common 
ancestor (Escriva et al., 2000). Phylogenetic analysis has identified three major 
subfamilies within this superfamily, based on their ligand-binding and DNA-binding 
properties. AR, together with the estrogen receptor (ER), progesterone receptor (PR), 
glucocorticoid receptor (GR), and mineralocorticoid receptor (MR) belong to the 
classical steroid receptor subfamily. These NRs undergo nuclear translocation upon 
ligand activation and usually bind as homodimers to inverted repeat DNA half sites. 
A second subfamily of NRs includes receptors for thyroid hormone (TR), vitamin D3 
(VDR), 9-cis retinoic acid (RXR), all-trans retinoic acid (RAR), and peroxisome 
proliferators (PPAR). This group of NRs is retained in the nucleus and usually binds 
to direct DNA repeats regardless of the presence of ligand. In addition, these 
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receptors exhibit promiscuous dimerization patterns, many involving heterodime-
rization with RXR. The majority of NRs identified to date form a third subfamily, so-
called orphan receptors, which share a close structural relationship with receptors for 
known hormones but have no known ligands. Although most of them bind DNA as 
homodimers on direct repeats, some interact with RXRs while others bind as 
monomers to half-site sequences (Wilson et al., 1993; Perlmann and Jansson, 1995). 
2.1 Structural features of AR 
The AR gene is a single-copy gene located on the long (q) arm of the X chromosome 
between positions 11.2 and 12 (see Figure 1). It spans approximately 90 kilobases of 
genomic DNA. The coding region of the AR gene consist of eight exons separated by 
seven introns and encodes a polypeptide product of around 910-919 amino acids that 
corresponds to a 110 kDa protein. 
2.1.1 Domain structure 
Like other members of the NR superfamily, the AR contains distinct structural and 
functional domains that are conserved among the nuclear receptor family members: 
an N-terminal transactivation domain (NTD or A/B), a DNA-binding domain (DBD), 
a hinge region, and a C-terminal ligand-binding domain (LBD).  
The NTD or A/B domain 
The N-terminal domain is the most variable both in size and sequence between NRs. 
In the case of AR, this domain is encoded by exon 1 that comprises more than half of 
the molecule (ca. 559 amino acids). It is involved in the transcriptional activation of 
target genes and contains a ligand-independent transactivation region, known as 
activation function 1 (AF-1). AF-1 is important for functioning of the full-length AR 
as its amino acid substitutions have been identified in patients suffering from 
androgen insensitivity and oligospermia (Gottlieb et al., 1999; Hiort et al., 2000). The 
NTD also contains three polymorphic direct repeats of glutamine (Glu), proline (Pro), 
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and glycine (Gly). Several studies have suggested that the change in the size of 
glutamine/glycine repeats alters the function of AR. The expansion of the size of the 
polyglutamine segment results in decreased AR transcriptional activity and is related 
to impaired spermatogenesis, infertility (Tut et al., 1997) and the spinal and bulbar 
muscular atrophy (Kennedy’s disease) (La Spada et al., 1991), whilst shorter 
glutamine and/or glycine repeats may be related to prostate cancer incidence 
(Edwards et al., 1999; Wang et al., 2004). In addition, the androgen receptor NTD 
domain contains two motifs that contribute to intramolecular interactions with the 















Figure 1. Schematic presentation of the AR gene and protein structure 
AR is coded by a 180-kb gene located on the long arm of the X chromosome (11q11.2). The gene has 
eight exons (boxes) and seven introns (lines). After transcriptional processing, mRNA is translated 
into a 919-amino acid-long protein. A number of functional domains are recognized in AR protein: 
The N-terminal transactivation domain with indicated positions of glutamine (Gln), proline (Pro), 
glycine (Gly) repeats (arrows) and transactivation function AF1 (line); the central DNA binding 
domain (DBD); the hinge region (HR) and the nuclear localization signal (NLS); and the C-terminal 
ligand binding domain with the ligand dependent transactivation function AF-2. Figure modified with 
permission from The Journal of Clinical Endocrinology & Metabolism (Litvinov et al., 2003); Courtesy of 
John T. Isaacs, Ph.D.   
 
AF2AF1
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The DBD domain 
The DBD domain, encoded by exons 2 and 3, is the best conserved domain among 
the members of the nuclear receptor superfamily. It is characterized by a high content 
of basic amino acids and by nine invariant cysteine residues, of which eight are 
implicated in the formation of two zinc finger motifs. The N-terminal located zinc 
finger interacts directly with hormone response elements of target genes in the major 
groove of the DNA. The ability to determine the specificity of AR interaction with 
DNA resides in three amino acids [Gly; Ser; Val], located in the proximal box (P-
box) at the base of the first zinc finger (Freedman, 1992). The second zinc finger 
helps to stabilize DNA receptor interaction and contains a five amino acid-long distal 
box (D-box), which participates in forming a dimerization interface for receptor 
monomers (Wong et al., 1993). Moreover, the AR DBD contains a non-classical 
nuclear export signal (NES) that mediates translocation from the nucleus (Black et 
al., 2001). 
The hinge region 
Located between the DBD and the LBD is a non-conserved hinge region, which can 
be considered as a flexible linker between the LBD and the rest of the receptor 
molecule. The hinge region is important for nuclear localization, containing a ligand-
dependent bipartite nuclear localization signal (NLS) that also spans the C-terminus 
of the DBD. The nuclear targeting signal contains the consensus motif KxKK which 
is subject to acetylation, thus modulating AR function (Fu et al., 2000). In addition, 
the hinge region of all mammalian AR contains a PEST [Pro; Glu; Ser; Thr] rich 
sequence, which may function in proteasome mediated androgen receptor turnover 
(Sheflin et al., 2000). 
The LBD domain 
The second best conserved region of NRs is the C-terminal hormone binding domain. 
This domain is encoded by a portion of exon 4 and exons 5-8, and is responsible for 
the specific high-affinity ligand binding. The LBD is formed by 12 conserved α-
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helixes and one β-sheet, together folded into a three-layered, antiparallel helical 
sandwich, creating a ligand-binding pocket for accommodation of ligand. Studies 
indicate that androgens interact with the LBD mainly through hydrophobic and 
hydrogen bonds (Matias et al., 2000). In addition to binding ligand, the LBD is also 
involved in dimerization, ligand-dependent coregulator recruitment and interaction of 
unliganded receptor with heat-shock protein (HSP) complexes. The LBD contains a 
ligand-dependent transactivation domain, known as activation function 2 (AF-2), 
which is also involved in interactions with coregulators (Slagsvold et al., 2000) and 
intramolecular interaction with the NTD (He et al., 2000). 
2.1.2 Post-translational modifications 
AR undergoes post-translational modifications, such as acetylation, ubiquitylation, 
sumoylation and phosphorylation (see Figure 2). These covalent changes may affect 
receptor stability, subcellular localisation and interactions with other proteins. Adding 
to the complexity, regulatory cross-talk between some of these modifications have 
been demonstrated (Fu et al., 2004; Rees et al., 2006). 
 





Figure 2. Schematic representation of the AR post-translational modification sites 
P: phosphorylation, A: acetylation, U: ubiquitylation, S: sumoylation. U? indicates that the exact 
ubiquitilation site has not been identified.  
 
AR is a phosphoprotein with multiple phosphorylation sites, mainly in the NTD. 
Most of these sites show increased phosphorylation in the presence of androgen, with 
the exception of Ser-94, which is constitutively phosphorylated. The kinases involved 
1 919
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in the phosphorylation of AR and the role of these modifications are still being 
debated. However, some studies suggest that MAPKs (Mitogen Activated Protein 
Kinases) and Akt play a role (Wen et al., 2000; Gioeli et al., 2006). Concerning 
acetylation, three lysines residues located in the hinge region at positions 630, 632 
and 633 have been identified as acetylation sites. They play a role in the modulation 
of transcriptional activity by favouring nuclear translocation and by balancing 
coactivator and corepressor binding (Fu et al., 2002). Furthermore, cross-talk with 
phosphorylation has been suggested based on the fact that AR acetylation mutants 
change the pattern of AR phosphorylation (Fu et al., 2004). AR, similar to other 
steroid receptors, is subject to ubiquitylation. Several of the enzymes involved in this 
modification have been identified; however, the exact sites and functional relevance 
of this modification are still missing. AR is also postranslationally modified by 
sumoylation, namely at K386 and K520 in the NTD (Poukka et al., 2000). AR 
sumoylation is hormone dependent and results in mainly repressive effects. 
Sumoylation involves SUMO-1-conjugating enzyme Ubc9 that binds AR within the 
hinge region (Poukka et al., 1999), raising the possibility of cross-talk between 
acetylation and sumoylation. 
2.2 AR transcriptional activation and regulation 
In its unliganded state, AR exists in the cytoplasm in a complex with heat shock 
proteins (HSPs) such as Hsp90, Hsp70, and Hsp56. The complex is essential for the 
generation of a high-affinity, ligand-binding conformation of AR. Upon ligand 
binding, AR undergoes a conformational change, dissociates from HSPs and becomes 
hyperphosphorylated. HSP release unmasks the dimerization motifs and NLS site of 
the receptor that allows dimerization with another ligand-bound AR and nuclear 
translocation. The homodimer translocates to the nucleus where it binds androgen 
response elements (AREs) located in the promoters and/or enhancers of various 
androgen regulated genes (see Figure 3).  
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Figure 3. Schematic presentation of AR transcriptional activation 
Testosterone (TST) diffuses into the cell or enters the cell through a sex hormone binding globulin 
(SHBG) receptor. TST is converted to 5α-dihydrotestosterone (DHT) by the enzyme 5α-reductase, 
and binds to the androgen receptor (AR). AR dissociates from the heat shock protein (HSP) complex, 
becomes phosphorylated and dimerize with another ligand-bound AR. The homodimer translocates 
to the nucleus where it binds to androgen response elements (AREs) of target genes, recruits 
coregulators and factors of the general transcriptional machinery. Transcription of AR target genes, 
mainly responsible for proliferation and differentiation, is induced. Figure reproduced with permission 
from (Klokk, 2007); Courtesy of Tove I. Klokk, Ph.D.    
 
Although AR normally functions as a homodimer, it has been found to 
heterodimerize with other NRs including ER (Panet-Raymond et al., 2000), GR 
(Chen et al., 1997) and TR4 (Lee et al., 1999). The consensus response elements 
identified for AR are composed of two palindromic hexanucleotide half sites 
separated by a three-nucleotide spacer (AGAACAnnnTGTTCT). Despite the very 
different physiological effects of steroids, these AREs are also recognized by GR, PR 
  GENERAL INTRODUCTION 
  14 
and MR. This paradox may be related to differential recruitment of coregulators upon 
the ligand-receptor interaction, although it remains to be further investigated. In 
addition, AREs composed of direct repeats and elements with modified site sequence 
have also been identified (Zhou et al., 1997; Geserick et al., 2005). After binding to 
ARE, AR initiates transcription of target genes through the recruitment of coregulator 
proteins, other transcription factors and factors of the general transcription apparatus. 
A schematic presentation of AR transcriptional activation is given in Figure 3. 
2.2.1 AR coregulators 
The transcriptional activity of AR, as well as other members of the NR superfamily, 
is influenced by coregulatory proteins. AR coregulators are generally defined as 
proteins that are recruited by AR and either enhance (coactivators) or reduce 
(corepressors) transactivation of target genes, without having significant effect on the 
basal transcription rate. In addition, coregulators do not typically possess DNA 
binding ability but contribute to AR mediated transcription through multiple 
mechanisms. Coregulators can influence AR transcription by acting with AR at the 
target gene promoter region to promote DNA occupancy, chromatin remodeling, 
histone modification, recruitment of general transcription factors associated with 
RNA polymerase II or by enabling the competency of the AR to direct target gene 
expression. The last mentioned can be achieved by modulating the appropriate 
folding of AR, ensuring its correct subcellular localization, facilitating ligand binding 
or intramolecular N/C interaction, thereby contributing to AR stability. In the last 
decade, an increasing number of proteins have been proposed to possess AR 
coactivating or corepressing characteristics (reviewed in Heinlein and Chang, 2002). 
A vast diversity of functions has been ascribed to these proteins, indicating that 
multiple cellular functions and signals regulate AR function. An overview of some 
well-known AR coregulators with their primary function is given in Table 1. 
  GENERAL INTRODUCTION 
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Table1. Overview of some well-known AR coregulators 
   Coregulator coA/coR *        Direct/Indirect *                 Function * 
ARA24 coA direct (NTD) Signal transducer 
ARA54 coA direct (LBD) Ubiquitination/proteasome 
ARA55 coA direct (LBD) Focal adhesion 
ARA70 coA direct (LBD) Nuclear receptor coregulator 
ARA160 coA direct (NTD) Nuclear receptor coregulator 
BAF57 coA direct (DBD-hinge) Chromatin remodeling complex 
BRG1 coA ND Chromatin remodeling complex 
hBRM coA ND Chromatin remodeling complex 
Calreticulin coR direct (DBD) Chaperone 
CARM1 coA indirect Histone methyltransferase  
Caspase 8 coR direct (NTD) Regulator of apoptosis 
CBP coA direct/indirect (DBD-hinge) Histone acetyltransferase  
Cyclin D1 coR direct (hinge) Cell cycle regulator 
Filamin coA direct (DBD,LBD) Cytoskeletal protein 
FLH2 coA direct (LBD) Focal adhesion 
HBO1 coR direct (DBD,LBD) Histone acetyltransferase  
HDAC1 coR direct (DBD,LBD) Histone deacetylase  
HDAC7 coR direct Histone deacetylase  
HDACs(several) coR indirect Histone deacetylase  
Hsp40,70,90 coA direct (LBD) Chaperones 
JHDM2A coA direct Histone demethylase  
JMJD2C coA direct Histone demethylase  
LSD1 coA direct (NTD,DBD,LBD) Histone demethylase  
NCoR coR direct/indirect (LBD) Nuclear receptor coregulator 
p300 coA direct/indirect (DBD-hinge) Histone acetyltransferase  
P/CAF coA direct/indirect (DBD-hinge) Histone acetyltransferase  
PRMT1 coA indirect Histone methyltransferase  
PTEN coR direct (DBD) Tumor suppressor 
SIRT1 coR direct (hinge) Histone deacetylase  
SMRT coR direct/indirect (NTD,LBD) Nuclear receptor coregulator 
SRG3 coA direct (DBD-hinge) Chromatin remodeling complex 
SRC1 coA direct (NTD,LBD) Scaffold protein, HAT activity 
SRC2 coA direct (NTD,LBD) Scaffold protein 
SRC3 coA direct (LBD) Scaffold protein, HAT activity 
Tip60 coA direct (hinge-LBD) Histone acetyltransferase  
Trap/Mediator coA direct Nuclear receptor coregulator 
coA/coR-coactivator/corepressor; Direct/Indirect-direct or indirect association with the AR; ND-not 
determined; HAT-histone acetyltransferase; NTD- binding to N-terminal domain of AR; DBD- 
binding to DNA binding domain of AR; LBD- binding to ligand binding domain of AR. * As 
reviewed in (Heinlein and Chang, 2002; Wang et al., 2005a) 
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Coactivators 
On a growing list of coactivators that regulate AR are the well studied coactivators of 
members of the p160 family of steroid receptor coactivator (SRC) family [SRC-1, 
SRC-2 and SRC-3], p300, the p300 homologue CREB binding protein (CBP), 
p300/CBP-associated factor (P/CAF), as well as Tat interactive protein 60 kDa 
(Tip60). In addition, protein arginine methyltransferases (PRMTs) such as 
coactivator-associated arginine methyltransferase 1 (CARM1) and protein arginine 
methyltransferase 1 (PRMT1) have also been shown to play a role in AR 
transactivation. The majority of these coactivators possesses histone acetyl 
transferase (HAT) or methyltransferase (HMT) activity and is believed to act mainly 
through histone acetylation or methylation, thus modifying chromatin structure. In 
addition to their effects on histones, some can act through functional modification of 
proteins such as transcription factors and coregulators. Noteworthy in this regard is 
the fact that AR itself is acetylated by p300, P/CAF and Tip60 at three lysine residues 
in its hinge region (Fu et al., 2000; Gaughan et al., 2002). The concept that 
demethylation of histones could be also involved in transcriptional activation by the 
AR has emerged only recently. Since then, lysine specific-demethylase 1 (LSD1), the 
Jumonji A (JMJA) domain-containing protein JMJD2A, and the Jumonji C (JMJC) 
domain-containing protein JMJD2C, that demethylate lysine 9 on histone 3, have 
been shown to interact with and function as coactivators for AR (Metzger et al., 
2005; Yamane et al., 2006; Wissmann et al., 2007). Several AR coactivators have 
also been identified as components of the ATP-dependent chromatin remodeling 
complex SWI/SNF, including the ATPases BRG1 and hBRM (Marshall et al., 2003), 
BAF57 (Link et al., 2005) and SRG3 (Hong et al., 2005). The recruitment of these 
proteins to the AR transcriptional complex is consistent with altered DNA topology 
following exposure to androgens. Another type of coactivator complex, that enhances 
ligand-dependent AR activity, is the multimeric thyroid hormone receptor (TR)-
associated protein (TRAP)-mediator complex (Wang et al., 2002a), which appears to 
influence the basal transcription machinery, possibly through the direct recruitment of 
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RNA polymerase II. Transcriptional activity of the AR also relies on coactivators that 
bind to the AR-LBD or AR-NTD, facilitating AR stability or nuclear transport. 
Among these are AR associated proteins (ARAs) [ARA24, ARA54, ARA55, ARA70 
and ARA160], the four and a half LIM domain protein (FHL2), filamin and Hsp40 
(reviewed in Heinlein and Chang, 2002). In addition to the above mentioned 
coactivators, several other AR coactivators have been identified. However, the 
precise mechanisms by which many of these modulate AR activity are yet to be 
determined. 
Corepressors 
Most of the AR coregulators identified to date have been shown to enhance 
transcription of AR. Nonetheless, AR corepressors also play critical roles in 
regulating AR activity. Corepressor complexes often contain histone deacetylase 
(HDAC) activity that alters the acetylation state of histones, thereby regulating AR-
mediated transcription. Cyclin D1 is an example of an AR interacting corepressor that 
functions through its ability to recruit HDACs and inhibit AR N/C interactions 
(reviewed in Burd et al., 2005). The two best characterized corepressors, the nuclear 
receptor corepressor (NCoR) and silencing mediator of retinoid and thyroid hormone 
receptor (SMRT), can directly associate with AR in the absence or in the presence of 
an agonist/antagonist and repress AR transactivation (Cheng et al., 2002; Liao et al., 
2003). Even though both NCoR and SMRT recruit HDACs to target genes, evidence 
for a direct functional linkage between a specific HDAC and corepressor for AR is 
still missing. Thus, NCoR and SMRT may exert their repressive effects through other 
mechanisms, such as inhibition of AR N/C interaction or preventing coactivator 
binding. In contrast to the indirect recruitment of HDACs to the AR transcriptional 
complex, HDAC7, Sir2 and HDAC1 can interact directly with AR and repress its 
ligand-induced signaling (Gaughan et al., 2002; Fu et al., 2006; Karvonen et al., 
2006). Similarly, calreticulin (Dedhar et al., 1994), the pro-apoptotic caspase-8 (Qi et 
al., 2007) and the phosphatase and tensin homolog deleted on chromosome 10 
(PTEN) tumor suppressor (Lin et al., 2004) interact directly with AR and repress its 
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transcriptional activity. However, these corepressors limit AR function by inhibiting 
AR nuclear translocation and/or DNA binding and not by direct repression of AR 
transcriptional activity. Another coregulator that associates with the AR and inhibits 
its activation is human origin recognition complex interacting protein (HBO1), a 
member of the MYST family (Sharma et al., 2000). The identification of HBO1 as an 
AR corepressor was surprising, as this protein contains HAT activity possessed by 
many coactivators. Nonetheless, the direct involvement of HBO1 enzymatic activity 
in its role as a corepressor has not yet been assessed. A number of other coregulators 
have been identified as AR corepressors. However, the mechanisms by which these 
corepressors inhibit AR transcativation remain to be elucidated.  
2.2.2 AR and specific transcription factors  
While there has been progress in describing the role of AR coregulators in AR 
dependent gene regulation, little is known about the roles of other DNA-binding 
transcription factors that may cooperate with AR in mediating androgen response. 
Over the last decade, numerous transcription factors have been shown to interact 
physically and functionally with the AR and regulate its transcription by different 
mechanisms. Some of these proteins interact directly with the AR and affect its 
ability to bind to AREs. One such example is dosage-sensitive sex reversal, adrenal 
hypoplasia critical region, on chromosome X gene 1 (DAX-1) transcription factor 
that binds to the AR LBD and potently inhibits androgen-dependent transcriptional 
activation as well as the N/C terminal interaction (Holter et al., 2002). Other proteins 
can compete with the AR for coregulators that are present in limiting amounts in cells 
(Aarnisalo et al., 1998; Fronsdal et al., 1998). Moreover, some transcription factors, 
including FoxA1, Oct1 and GATA2 can bind DNA sequences in close proximity to 
AREs and cooperate to regulate AR target gene expression (Wang et al., 2007). The 
presence of these collaborating transcription factors may assist AR in binding to sites 
other than canonical AREs. Furthermore, some of these factors may function as 
pioneer factors that alter chromatin to permit AR binding. Overall, these studies 
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indicate that a hierarchical network of transcription factors with distinct functional 
roles can regulate distinct steps in AR dependent gene transcription. 
 
3. Glucocorticoid Receptor  
Glucocorticoids, a major subclass of steroid hormones, were originally named for 
their ability to influence glucose metabolism. During fasting, glucocorticoids help to 
maintain blood glucose levels by increasing for example gluconeogenesis, glycogen 
release, lipolysis and protein catabolism. In addition, glucocorticoids have effects on 
mood, cognitive functions and are important for inflammation and immune responses 
(reviewed in McMaster and Ray, 2007). Glucocorticoids are produced by the adrenal 
cortex and their biological effects are mediated via a 94-kDa intracellular protein, the 
glucocorticoid receptor (GR). GR is a member of the nuclear receptor superfamily 
and is one of the close relatives of AR. Like other steroid receptors, the GR consists 
of a variable N-terminal domain that also contains transactivation domain 1 (τ1), a 
central DNA binding domain with two zinc finger motifs, a hinge region, and a C-
terminal hormone binding domain that harbors a second transactivation domain (τ2). 
GR exists in a number of splice variants that are expressed at different levels in 
different cell types and have differential activity on gene regulation (reviewed in Lu 
and Cidlowski, 2004). These include, for example, the conventional ligand binding 
GR termed GRα and a C-terminal variant that does not bind ligand, GRβ, which may 
have a dominant negative effect on GRα. In addition, it was reported that multiple 
proteins are translated from the GRα transcript, further increasing the diversity of GR 
protein expression (Lu and Cidlowski, 2005). 
3.1 GR transcriptional activation and regulation 
In its inactive, unliganded state GR is found predominantly in the cytoplasm 
complexed with HSPs, although a small fraction of GR/HSP complex may reside in 
the nucleus (Wikstrom et al., 1987), or recirculate to the nuclear compartment (Hache 
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et al., 1999). Independent of its intracellular localization, the main function of the 
GR/HSP complex is to keep the receptor protein in an inactive, ligand-activable state. 
Similar to AR, GR undergoes a conformational change upon ligand binding, 
dissociates from the HSP complex, becomes hyperphosphorylated, homodimerizes 
with another activated GR molecule and if cytoplasmic, translocates to the nucleus. In 
the nucleus, GR binds to glucocorticoid response elements (GREs) in promoters or 
enhancers of target genes, thereby inducing or repressing gene transcription 
(reviewed in Schoneveld et al., 2004). However, GR can also act as a monomer and 
modulate the transcriptional rates of non-GRE-containing genes by interacting with 
nuclear transcription factors, including activator protein-1 (AP-1), nuclear factor κB 
(NFκB) and signal transducer and activator of transcription 5 (STAT5) (reviewed in 
Bamberger et al., 1996). When associated with its response elements, GR initiates 
gene transcription through the recruitment of coregulatory complexes that modify and 
remodel chromatin, promoting a more open structure and further assembly of the 
basal transcriptional machinery (Baumann et al., 2001; McKenna and O'Malley, 
2002; Kinyamu and Archer, 2004; O'Malley, 2004; Stavreva et al., 2004). Like other 
members of the steroid receptor subfamily, GR is subject to post-translational 
modifications, including phosphorylation, acetylation, ubiquitination and 
sumoylation (reviewed in Faus and Haendler, 2006). These may affect its 
transcriptional activity, stability and interactions with other receptors. 
 
4. Nuclear receptor dynamics 
4.1 Transcriptional action of NRs 
AR and nuclear receptors in general mediate the action of their specific ligands 
through interaction with chromatin and protein-protein interactions with a variety of 
coregulators and basal transcription factors. The dynamic process by which the 
receptors recruit these factors to activate transcription was until recently poorly 
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understood. Currently, two opposing views exist for the development of 
transcriptional complexes on nuclear receptor regulated promoters: the classical view 
and the dynamic view, which are reviewed below. 
4.1.1 The classic model 
The classic model of nuclear receptor function proposes stable binding of the 
liganded receptor to the promoter. According to this view, nuclear receptors are 
stably associated with their recognition sites in promoters of target genes for as long 
as the ligand is present in the cellular milieu, serving as a platform for the sequential 
assembly of large transcriptional complexes (Shang et al., 2002). These complexes 
would have long residence times on the template, measured in minutes or hours. 
Indeed, AR activity was shown to involve sustained chromatin association with 
regulatory regions (Wang et al., 2005b). The occupancy of the AR-coactivator 
complex on regulatory regions increases gradually after androgen exposure, peaking 
at 16 hours and then gradually declining following longer stimulation. In contrast to 
AR, the ER transcription complex appears to cycle onto and off target promoters 
under continuous stimulation by estrogen, leading to a cyclical induction pattern with 
a periodicity of 40-60 minutes, at least on the well characterized ER target gene pS2 
promoter (Shang et al., 2000). Even though the cyclic assembly of ER transcription 
complexes is a dynamic event, the central concept of a slow evolution of factor 
complexes (i.e. long term residency measured in 10s of minutes) remains. Evidence 
supporting this model has been obtained mainly from experiments based on 
chromatin immunoprecipitation (ChIP) studies. In the case of AR, ChIP studies have 
focused mainly on two AR target genes, prostate-specific antigen (PSA) and 
Kallikrein 2 (KLK2) (Kang et al., 2004; Wang et al., 2005b). Although the ChIP 
assay is a powerful tool to assess promoter occupancy and complex formation, it 
remains limited by the biochemical nature of the technique. Due to the difficulty in 
sample preparation and the need of fixation, ChIP cannot detect rapid protein 
movements. Furthermore, ChIP can assess the promoter occupancy only indirectly, 
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and thus it cannot confirm whether proteins are truly in a complex on a promoter. It 
can only show that they are somehow associated with the promoter sometime during 
the course of fixation. In addition, the results represent the promoter occupancy of an 
averaged cell population and cannot account for heterogenous cell responses. These 
features need to be considered in interpreting ChIP data. 
4.1.2 The dynamic model 
Recent studies making use of technological advances in live cell microscopy and 
genetically engineered cell lines challenged the classical view of stable template 
bound receptor complexes. This led to the proposal of an alternative, dynamic model 
for nuclear receptor action, called the “hit-and-run” model. According to this model, 
the receptor interacts transiently with the promoter, recruits other factors, and is itself 
dynamically displaced from its target sites (Hager et al., 2002). In contrast to the 
static view of receptor action, the residence time of NRs and interacting coregulators 
on the promoter would be measured in seconds, rather than minutes or hours. 
Evidence for this model was first provided by demonstration of the rapid exchange of 
green fluorescent protein (GFP)-tagged GR between chromatin and the 
nucleoplasmic compartment on a tandem array of mouse mammary tumor virus 
(MMTV) promoters, using fluorescence recovery after photobleaching (FRAP) and 
fluorescence loss in photobleaching techniques (FLIP) (McNally et al., 2000).  
Tagging the protein of interest with GFP and use of photobleaching techniques, such 
as FRAP and FLIP, allows a real time view of protein interactions with the chromatin 
template in live cells. In order to visualize and measure real-time mobility of NRs on 
their specific regulatory elements, the regulatory sites must be amplified in the 
chromosome. This was accomplished by constructing an artificial array with 200 
copies of the steroid hormone receptor inducible MMTV promoter that contains 
HREs to which steroid receptors can bind directly (McNally et al., 2000) (see Figure 
4).  
  GENERAL INTRODUCTION 
  23 
                           
Figure 4. Schematic representation of the MMTV array 
200 copies of a 9 kb repeat of the mouse mammary tumor virus (MMTV) promoter integrated into 
the host chromosome 4, creating a head-to-tail MMTV array. The MMTV promoter adopts a specific 
chromatin organization consisting of six positioned nucleosomes (A-F). Nucleosome B-C region of 
the MMTV long terminal repeat (LTR) contains hormone response elements (HREs) to which 
liganded nuclear receptors (NRs) can bind and regulate the transcription of a reporter gene (Rep). 
Figure reproduced with permission from (Klokk, 2007); Courtesy of Tove I. Klokk, Ph.D.   
 
The MMTV array thus became a useful model system for the real-time study of 
protein-chromatin interaction dynamics, chromatin structure and promoter occupancy 
in relation to transcription. Similar high mobility of other transcription factors, 
including nuclear receptors as ER (Stenoien et al., 2001b), PR (Rayasam et al., 2005) 
and AR (Klokk et al., 2007), and transcription related factors (Stenoien et al., 2001b; 
Becker et al., 2002) have been demonstrated in the same or similar systems. Overall, 
from these studies a new insight into NR-mediated transcription has emerged that is 
based on highly dynamic interactions between the NR and the chromatin template. 
Schematic presentation of the hit-and-run model for AR action is presented in Figure 
5. 
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Figure 5. Hit-and-run model for AR action 
AR bound to the agonist 5α-dihydrotestosterone (DHT) dissociates from the heat shock protein (Hsp) 
complex, translocates to the nucleus where it binds to androgen response elements (AREs) of target 
genes. Coregulator proteins are recruited, including chromatin remodeling complexes (SWI/SNF), 
coactivators (SRC), coactivators with histone acetyl transferase activity (CBP) and RNA polymerase 
II (PolII). The chromatin is remodeled, followed by association of a transcription initiation complex. 
AR is dynamically displaced (symbolized by the arrows) and shuttles between the chromatin-bound 
and free nucleoplasmic state with a half-maximal recovery time, t1/2 of approximately 5 seconds. AR 
bound to the antagonist hydroxyflutamide (OHF), similar to agonist-bound AR, dissociates from 
(Hsps) and translocates to the nucleus. However, because of conformational changes induced by 
OHF, corepressors as NCoR and SMRT are recruited, leading to further recruitment of molecules, 
such as histone deacetylases (HDACs), which keep the chromatin in a compact state and inhibit the 
assembly of the transcription initiation complex. AR is displaced and shuttles between the chromatin-
bound and free nucleoplasmic state with a half-maximal recovery time, t1/2 of approximately 0.5 
seconds. These rapid, stochastic interactions of AR with chromatin are influenced by the nature and 
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4.1.3 The “static” versus “dynamic” view 
The differences in nuclear receptor dynamics seen with live-cell approaches (time 
scale of seconds) and ChIP assays (time scale of minutes to hours) arise in part from 
the different time scales studied by these techniques. However, it has been proposed 
that these two apparently opposing views can be integrated into one consistent model 
(Hager et al., 2006; Metivier et al., 2006). The “return to template” model suggests 
that NRs exist in the nucleoplasmic space in various coregulator complexes that 
rapidly interact with their target regulatory site. Most of these rapid, transient binding 
events are stochastic and nonproductive, with only a small fraction resulting in 
template modification or the recruitment of alternate complexes. Thus, the promoter 
evolves through multiple specific events that modulate the receptor complex stability 
and initiation of transcription. In addition, both receptors and their coregulators are 
subject to modifications, which may alter the activity of the complex. Whereas FRAP 
experiments detect rapid and nonproductive binding of factors, ChIP assays would 
determine associations of productive complexes at a specific stage of promoter 
development, averaged over large number of cells, giving the impression of a 
statically bound complex. The rapid exchange of factors on promoters favors rapid 
activation and efficient promoter function and thus is very important for the cell to 
respond to changes in the environment. Alternatively, some genes that do not require 
a rapid response may still contain stable complexes. This suggests that individual 
promoters achieve transcription in different ways, depending on their architecture.  
4.2 Mechanisms contributing to NR mobility 
Despite the increasing number of transcription factors and their complexes that have 
been found to be highly mobile within the nucleus, the mechanisms involved in this 
behavior are yet not well understood. Current studies propose that several parameters 
affect and/or influence observed dynamic protein-chromatin interactions, including 
chromatin remodeling complexes, molecular chaperones, the proteasome degradation 
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apparatus, specific ligands, and modification of histones (reviewed in Hager et al., 
2004) which are briefly reviewed below. 
4.2.1 Ligand-specific dynamics of NRs 
Live cell imaging experiments revealed that dynamics of steroid/nuclear receptors, 
such as GR (McNally et al., 2000), ER (Stenoien et al., 2001b), PR (Rayasam et al., 
2005) and AR (Klokk et al., 2007), are strongly influenced by the nature of their 
ligands. For example, it has recently been shown in our laboratory that there is a 
significant difference between the dynamics of the AR-chromatin interactions in the 
presence of an agonist and that of an antagonist (anti-androgen) at an HRE in living 
cells (Klokk et al., 2007). Agonist-bound AR exhibits an approximately 10-fold 
slower FRAP recovery kinetics compared to antagonist–bound AR, suggesting that 
recovery kinetics is connected to transcriptional activity (see Figure 5). Furthermore, 
PR and GR have faster exchange rates compared to AR, indicating that receptors may 
use different mechanisms for interaction with their promoters. In general, the slower 
turnover rates of agonist/antagonist bound receptors might reflect the time needed for 
coregulator recruitment and assembly of the transcription machinery. In addition, 
mobilities of steroid receptors might also be affected by their ligand-induced 
conformational changes.  
4.2.2 Chromatin remodeling and NR dynamics 
The basic repeating unit of chromatin, the nucleosome, consists of 146 bp of DNA 
wrapped around an octamer of core histones, which is made of two copies each of the 
histone proteins H2A, H2B, H3, and H4. In addition to the four core histones, the 
linker histone H1, associates with DNA between nucleosomes and may facilitate the 
formation of larger chromatin fibers (higher order chromatin), leading to a fully 
condensed chromosome. The organization of DNA into chromatin restricts the access 
of promoters to regulatory proteins and the transcriptional machinery. This structural 
restriction of chromatin is overcome by two distinct classes of chromatin-remodeling 
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complexes: those that covalently modify histones (reviewed in Kouzarides, 2007) and 
those that rearrange the organization of the nucleosomes in the chromatin fiber in an 
ATP-dependent manner (Vignali et al., 2000; Chen et al., 2006). Recent data suggest 
that these complexes affect NR mobility and disassembly, in addition to their central 
role in remodeling (Fletcher et al., 2000; Nagaich et al., 2004; Metivier et al., 2006). 
ATP-dependent chromatin remodeling complexes 
ATP-dependent complexes use the energy derived from ATP hydrolysis to directly 
alter the position and/or stability of nucleosomes. They contain a core ATPase 
catalytic subunit that belongs to the Swi2/Snf2 superfamily of DNA helicases. Based 
on the identity of this subunit, five major families of ATP-dependent remodeling 
complexes have been described: SWI/SNF, ISWI, Mi-2/NuRD, INO80, and SWR1. 
Among them, the SWI/SNF family was the first identified and thus has been the best 
characterized. The human SWI/SNF complex contains one of two catalytic ATPase 
subunits, BRG1 or BRM, and several accessory BRG1-associated factors (BAFs). 
Although the BRG1 subunit of the SWI/SNF complex has been shown to be the 
primary component with regard to GR (Fryer and Archer, 1998) and PR (Mymryk 
and Archer, 1995) action, AR activity shows a strong dependence on the BRM 
subunit (Marshall et al., 2003). Results obtained over the last years demonstrate that 
the SWI/SNF remodeling complexes are also implicated in nuclear receptor 
dynamics. Using the template pull-down assays, both GR (Fletcher et al., 2002) and 
PR (Rayasam et al., 2005) were shown to be actively displaced from the nucleosome 
array during the process of chromatin remodeling, as a direct consequence of 
SWI/SNF action. In addition, recruitment of chromatin remodeling complexes by PR 
and GR were found to be ligand-dependent and the type of ligand associated with the 
PR, affected its displacement from chromatin during the process of remodeling. 
These results were more recently also extended to the AR (Klokk et al., 2007). The 
findings described above suggest that steroid receptors, in their liganded form, can 
recruit the ATPase subunit of the SWI/SNF complex, which is involved in their 
dynamic association with the chromatin template. 
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Histone modifications 
The amino-terminal tails of histones are subject to a variety of reversible 
posttranslational modifications. At least eight distinct types of histone modifications 
have been identified to date, including acetylation, methylation, phosphorylation, and 
ubiquitination (Table 2). These alternations are directed by chromatin remodeling 
complexes that consist of the specific histone modifying enzymes (for example, 
kinases, histone acetyltransferases, methyltransferases, and ubiquitin ligases) 
(reviewed in Kouzarides, 2007). 
 
Table 2. Modifications identified on histones 
 Modifications     Residues modified              Modifying enzymes 
Acetylation K-ac Acetyltransferases (HATs) 
Methylation (lysines) K-me1 K-me2 K-me3 Lysine methyltransferases (HKMTs) 
Methylation (arginines) R-me1 R-me2a R-me3s Arginine methyltransferases (PRMTs) 
Phosphorylation S-ph T-ph  Serine/Threonine kinases 
Ubiquitylation K-ub Ubiquitilases 
Sumoylation K-su Sumoylases 
ADP ribosylation E-ar ADP-ribosyltransferases 
Deimination R → Cit Peptidyl arginine deiminases 
Proline isomerization P-cis > P-trans Proline isomerases 
Overview of different modifications identified on histones. Modified residues: Lys (K), Arg (R), Ser 
(S), Thr (T), Glu (E), Pro (P) and Arg (R) to citrulline (C), and enzymes that direct each modifi- 
cation are shown. Modified from (Kouzarides, 2007). 
 
Histone modifications may alter chromatin structure by influencing contacts between 
different histones in adjacent nucleosomes or the interaction of histones with DNA, 
or by recruitment of nonhistone proteins. However, current experimental evidence 
favors the view that histone modifications are epigenetic markers that facilitate the 
recruitment of chromatin binding proteins to dictate a distinct chromatin structure 
(histone code hypothesis) (Jenuwein and Allis, 2001). A number of proteins have 
been identified that are recruited to specific modifications and bind via specific 
domains. For example, acetylated histones are recognized by bromodomains (Yang, 
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2004), whereas chromodomains and PHD domains associate with methylated 
histones (Brehm et al., 2004), and 14-3-3 proteins bind phosphorylated histone H3 
(Macdonald et al., 2005). The presence of such histone specific protein domains in 
some of ATP-dependent chromatin remodeling complexes indicates that there is a 
functional relationship between ATP-dependent chromatin remodeling complexes 
and histone modification. The most studied histone modifications are the acetylation 
and deacetylation of histone lysine residues which are reviewed below. 
Histone acetylation 
Histone acetylation is catalyzed by the enzymatic activities of histone 
acetyltransferases (HATs) that are divided into three main families: GNAT, MYST, 
and CBP/p300 (reviewed in Lee and Workman, 2007). Acetylation of histones 
neutralizes positively charged lysine side chains, which could weaken histone-DNA 
or nucleosome-nucleosome interactions, thereby creating a more open chromatin 
structure and enhance its accessibility to multiple transcription factors, such as the 
transcription complex. Indeed, acetylated chromatin has long been associated with 
transcriptionally active genes, with the rate of transcription correlating positively with 
the degree of histone H3 and H4 acetylation (Berger, 2002). In agreement with this 
many transcription coactivators that are recruited to target promoters by transcription 
activators, such as NRs, contain intrinsic HAT activity (Kuo and Allis, 1998). These 
include CBP/p300, P/CAF, TATA binding protein-associated factor (TAF) II250, and 
the p160 family of coactivators. ChIP assays analyzing the timing of recruitment of 
different coregulators after ligand treatment have revealed that HAT containing 
complexes, similar to other coregulators, are recruited to target promoters in a 
dynamic manner and in a specific order (Metivier et al., 2006). The ordered 
recruitment of coactivators, changes in histone modifications and the recruitment of 
the transcription machinery, which leads to gene expression, were shown to correlate 
with cyclical recruitment of ER to the pS2 promoter. Additional transcription 
responses mediated by other NRs, such as AR and PR, have shown similar dynamic 
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temporal pattern of coactivator recruitment and histone modifications (Kang et al., 
2004; Aoyagi and Archer, 2007). These findings indicate that association of 
HATs/HDACs complexes with target promoters and following changes in histone 
acetylation contribute to NR dynamics and promoter clearance.  
Histone deacetylation and HDAC inhibitors 
Acetylation of histones can be reversed by deacetylation that is catalysed by histone 
deacetylases (HDACs). Mammalian HDACs have been classified into four classes 
based on sequence homology to the yeast HDACs: class I (HDACs1-3 and HDAC8), 
class II (HDACs 4-7, HDAC9 and HDAC 10), class III (Sirt1-Sirt7), and class IV 
(HDAC11) which has properties of both class I and classII. Class III HDACs, so-
called sirtuins, are homologs of yeast Sir2 and form a structurally distinct class of 
nicotinamine adenine dinucleotide (NAD)-dependent enzymes. HDACs remove the 
acetyl groups from histone lysine side chains, thus re-establishing the positive charge 
of histones and the less accessible form of chromatin that is commonly associated 
with transcriptional repression. In contrast to HATs, HDACs are often found as 
components of transcriptional repressor complexes such as NCoR and SMRT (Tsai 
and Fondell, 2004). Although HDACs have been generally correlated with gene 
repression, there are several examples where HDACs appear to be required for gene 
activation, thus functioning as coactivators (Berghagen et al., 2002; Wang et al., 
2002b;  Ferguson et al., 2003;  Mulholland et al., 2003; Qiu et al., 2006).  
The correct balance between HAT and HDAC activity plays an important regulatory 
role in gene expression. In addition to transcriptional regulation, HAT–HDAC 
interplay is also linked to other chromatin-associated processes such as replication, 
site-specific recombination and DNA repair, thereby playing a major role in 
modulating overall cellular fate (reviewed in Kouzarides, 2007). Increasing evidence 
indicates that alternations in HAT/ HDAC genes (such as translocation, amplification, 
over-expression or mutation) are connected to tumor growth and cancer (Cress and 
Seto, 2000). For example, histone deacetylation by HDACs may be a mechanism for 
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silencing some tumor suppressor genes responsible for cell progression, cell 
proliferation, differentiation and apoptosis. Inhibition of HDACs, and thereby 
activation of silenced genes, is therefore of interest in cancer therapy. To date, several 
natural and synthetic compounds with HDAC inhibitor (HDACi) activity have been 
identified. With a few exceptions, they can be divided into five main classes: 
hydroxamic acids, short-chain fatty acids, cyclic peptides, benzamides, and 
electrophilic ketones (reviewed in Minucci and Pelicci, 2006). Even though the action 
of HDACis in tumorigenesis has been explored and some of them are in clinical 




5. Aim of the study 
The main aim of this work was to study the molecular mechanisms by which AR 
regulates transcription. Previous studies suggested that the transcriptional activity of 
AR, as well as other steroid receptors, correlates with receptor mobility in the nucleus 
(Klokk et al., 2007). Furthermore, the dynamic behavior of AR was shown to be 
influenced by the nature of ligand (Klokk et al., 2007) and by changes in histone 
acetylation at the target promoter (results from Saatcioglu laboratory, unpublished 
data). However, other steroid receptors, such as GR, have been shown to have 
differential responses to changes in histone acetylation at the same promoter, 
compared to AR. To elucidate what links histone acetylation to the changes in AR 
dynamics, it is necessary to know the details of AR-chromatin interactions and the 
associated proteins at AR response elements under these conditions. The aim of this 
study was thus to examine in more detail local acetylation status of the MMTV 
promoter during AR-mediated transcriptional activation; this was compared with that 
of GR-mediated transactivation at the same response element. 
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Androgen and glucocorticoid receptor 
mediated changes in histone acetylation             
at the MMTV promoter 
 
1. Summary 
Post-translational modifications of histones play an important role in regulation of 
gene transcription. The most well studied histone modification is acetylation that is 
regulated by the enzymatic activities of histone acetyl transferases (HATs) and 
histone deacetylases (HDACs). Histone acetylation has generally been associated 
with transcriptional activation and deacetylation with repression. However, there are 
a number of genes for which activation is associated with deacetylation. Previous 
results from our laboratory show that increased histone acetylation induced by the 
HDAC inhibitor Trichostatin A (TSA) reduced androgen receptor (AR) mobility at 
the mouse mammary tumor virus (MMTV) promoter, concomitant with an increase in 
transcriptional activity. The effect of TSA was specific to AR as the dynamics and 
transcriptional activity of the glucocorticod receptor (GR), another ligand-regulated 
transcription factor of the steroid receptor family, was not affected by TSA. These 
data further demonstrated that histone acetylation does not always induce 
transcription, but is dependent on promoter and transcription factor context. In this 
study, the impact of TSA on the acetylation level of histones H3 and H4 at the 
MMTV promoter during AR- and GR-mediated transcriptional activation was 
investigated. Chromatin immunoprecipitation (ChIP) analysis revealed no significant 
change in histone acetylation at the MMTV promoter following TSA treatment, even 
though global levels of histone acetylation were greatly increased. Furthermore, 
global acetylation of histones occurred independently of the presence of androgen or 
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glucocorticoid. These results demonstrate that although TSA treatment induces a 
global increase in histone acetylation, specific locations of the genome, such as the 
MMTV promoter may be relatively unaffected. Interestingly, androgen treatment 
resulted in a decrease in the basal histone H3 acetylation level at the MMTV 
promoter. Preliminary studies suggest a different acetylation profile of histone H3 in 
the presence of GR compared to AR. However, additional studies are necessarry to 




Androgens play a critical role in the development and maintenance of the male 
reproductive system and are involved in important physiological and pathological 
processes, such as normal prostate biology and prostate cancer (Jenster, 1999). The 
effects of androgens are mediated by the androgen receptor (AR), a ligand-regulated 
transcription factor that belongs to the nuclear receptor superfamily. Like other 
members of this family, AR is characterized by a structure composed of four distinct 
functional domains: an N-terminal transactivation domain (NTD) containing a ligand-
independent activation function 1 (AF-1), a DNA-binding domain (DBD), a hinge 
region, and a ligand binding domain (LBD) possessing a ligand-dependent activation 
function 2 (AF-2). AR is a steroid hormone receptor which together with the closely 
related estrogen receptor (ER), progesterone receptor (PR), glucocorticoid receptor 
(GR), and mineralocorticoid receptor (MR), form a subfamily of steroid hormone 
receptors. Upon ligand binding, steroid receptors change conformation, bind to their 
cognate hormone response elements (HREs) in promoters and/or enhancers of target 
genes and modulate transcription through the recruitment of chromatin modifying 
and remodelling complexes, coregulators, additional transcription factors as well as 
the components of the basal transcription machinery (Dilworth and Chambon, 2001; 
Hager, 2001; Marshall et al., 2003; Metivier et al., 2003; Wang et al., 2005a). The 
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classical view of steroid/nuclear receptor function suggests the static binding of the 
liganded receptors to regulatory elements in chromatin, which serves as a platform 
for the assembly of large transcriptional complexes (McKenna and O'Malley, 2002; 
Shang et al., 2002).  
Advances in green fluorescent protein (GFP) technology and live-cell microscopy 
have led to the discovery of new principles for transcription factor action and the 
proposal of an alternative “hit-and-run” model (reviewed in Hager et al., 2006). 
According to this model, receptors interact only transiently with their HREs, recruit 
other factors and are dynamically displaced from the promoter. Dynamic movement 
on target promoters have been characterized for the steroid receptors GR (McNally et 
al., 2000), PR (Rayasam et al., 2005), ER (Stenoien et al., 2001a), and AR (Klokk et 
al., 2007), as well as for several other DNA binding proteins (Becker et al., 2002). In 
addition, various factors have been demonstrated to influence receptor mobility 
(reviewed in Hager et al., 2004). These include, among others, chromatin remodelling 
complexes, specific ligands and histone modifications. Indeed, it was revealed in our 
laboratory that dynamic interactions of AR are strongly dependent on the nature of 
the ligand, as agonist-bound AR had reduced mobility compared to antagonist-bound 
AR (Klokk et al., 2007). Moreover, longer residence time in the presence of agonist 
coincided with the recruitment of the ATPase BRM, chromatin remodeling and 
transcriptional activation. The involvement of specific ligands and the chromatin 
remodelling complex SWI/SNF in receptor mobility and transcriptional activation has 
also been demonstrated for other steroid receptors such as PR (Rayasam et al., 2005) 
and GR (Fletcher et al., 2002).  
In addition to chromatin remodelling, the accessibility of promoters and 
transcriptional activity are also regulated by histone modifications (Berger, 2002). 
These are thought to contribute to the changes in histone-histone and histone-
chromatin interactions that could lead to modulation of chromatin structure. Histone 
modifications can also act as signals for recruitment of additional chromatin-
modifying factors, leading to changes in chromatin architecture and gene regulation 
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(Strahl and Allis, 2000; Jenuwein and Allis, 2001). In particular, acetylation of lysine 
residues within the N-terminal tails of histone proteins has been well studied in the 
context of gene regulation. Histone acetylation is regulated by the actions of histone 
acetyl transferases (HATs) and histone deacetylases (HDACs). The dynamic 
interplay between HATs and HDACs is thought to regulate histone acetylation at 
cellular and local promoter level (Struhl, 1998). Acetylation of histones has long been 
associated with transcriptional activation (Allfrey et al., 1964) and with an “open” 
and accessible chromatin conformation (Kuo and Allis, 1998; Verdone et al., 2005). 
In contrast, histone deacetylation is commonly correlated with gene repression and a 
more “closed”, non-accessible form of chromatin. This view was solidified when 
several transcriptional coactivators, recruited to target genes, were identified to 
possess HAT activity, whereas many corepressor complexes were found in 
association with HDACs (Xu et al., 1999; Hu and Lazar, 2000; Tsai and Fondell, 
2004).  
However, a number of studies provide evidence that the relationship between histone 
acetylation and transcription is more complicated as transactivation of some 
promoters is associated with deacetylation. For instance, the treatment with histone 
deacetylase inhibitors (HDACis) that results in hyperacetylation of histones, showed 
inhibitory effects on steroid-inducible promoters, such as ER regulated ovalbumin 
promoter (McKnight et al., 1980) and mouse mammary tumor virus (MMTV) 
promoter regulated by GR (Bresnick et al., 1990; Mulholland et al., 2003).  
The steroid-regulated MMTV promoter that assumes a well-defined chromatin 
structure when stably integrated into the host genome (Richard-Foy and Hager, 1987) 
has been a useful model system to study the relationship between chromatin structure, 
receptor dynamics and transcriptional activation. Previously, it has been shown that 
AR transcriptional activity on the MMTV promoter is induced by HDACi TSA (List 
et al., 1999). More recent results in our laboratory revealed that increased histone 
acetylation induced by the HDACis TSA and SAHA resulted in increased 
transcriptional activity of agonist bound AR, which correlated with reduced mobility 
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of AR at the MMTV promoter (unpublished data). The effect of HDACis on AR 
transcriptional activity and dynamics was receptor specific, as another member of the 
steroid hormone receptor family, GR, has been shown to have differential responses 
to changes in histone acetylation at the same promoter (unpublished data). It was 
previously reported that, in contrast to AR, TSA had inhibitory effect on GR activity 
on the MMTV promoter (Bresnick et al., 1990; List et al., 1999; Mulholland et al., 
2003). In addition, results in our laboratory showed that transcriptional activity and 
mobility of agonist bound GR were not affected by the HDACis TSA or SAHA on 
the MMTV promoter, supporting the notion that reduced mobility of AR in response 
to HDACi was directly correlated with transcriptional activity. However, what links 
histone acetylation to the changes in AR dynamics and the molecular details 
underlying the differential response of AR and GR to HDAC inhibitors in the same 
promoter background is currently not clear. It was therefore of interest to examine the 
local acetylation status of the MMTV promoter in response to the HDAC inhibitor 
TSA during AR- and GR-mediated transcriptional activation that could possibly 
contribute to changes in receptor dynamics and transactivation potential. 
 
3. Materials and Methods 
3.1 Materials 
Dulbecco’s Modified Eagle Medium (DMEM), DMEM-without Phenol Red, L-
glutamine, Penicillin/Streptomycin and Trypsin/EDTA were purchased from 
BioWhittaker, Cambrex Bio Science and fetal calf serum (FCS) was purchased from 
PAA Laboratories GmbH. The following reagents were obtained from Sigma-
Aldrich: Bovine serum albumin (BSA), magnesium chloride (MgCl2), puromycin, 
dithiothreitol (DTT), β-glycerophosphate, sodiumortovanadate (Na3VO4), HEPES, 
Tween 20, leupeptin, phenylmethylsulphonyl-fluoride (PMSF), octyl phenoxy 
polyoxy ethanol (Triton X-100), sodium azide (NaN3), trichostatin A (TSA), 
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dexamethasone (DEX), tetracycline, formaldehyde, phenol chloroform-isoamyl 
alcohol (25:24:1), lithium chloride (LiCl), sodium deoxycholate, sodium butyrate, 
yeast transfer ribonucleic acid (tRNA), NP-40/Igepal CA-630, anti-α-Tubulin mouse 
monoclonal antibody, horseradish peroxidase-conjugated (HRP) anti-rabbit IgG 
antibody and HRP-conjugated anti-mouse IgG antibody. Sodium chloride (NaCl), 
sodium hydroxide (NaOH) and ethylenediaminetetraacetic acid (EDTA) were 
purchased from BDH Chemicals Ltd. and sodium dodecyl sulphate (SDS) was 
obtained from Fluka Chemie GmbH. Methanol, trisaminomethane (Tris), 
hydrochloric acid (HCl) were obtained from VWR International, Inc. and glycine was 
from Duchefa Biochemie BV. Skim milk powder was from Acumedia Manufacturers, 
Inc. and salmon sperm DNA, Protein A Sepharose (liquid beads) and anti-GFP rabbit 
fraction antibody were purchased from Invitrogen. Lightcycler® 480 SYBR Green I 
Master mix, Lightcycler® Multiwell Plates 96, Protease inhibitor cocktail and 
proteinase K were obtained from Roche Diagnostics GmbH. Protein A Sepharose 
(powder beads) and ECL Western Blotting Analysis System were purchased from GE 
Healthcare Bio-Science. Anti-acetyl-histone H3, anti-acetyl-histone H4 and anti-AR 
rabbit polyclonal antibodies were obtained from Upstate Biotechnology, Inc. and 
another anti-AR rabbit polyclonal antibody (N-20) was from Santa Cruz 
Biotechnology, Inc. Anti-histone H3 rabbit polyclonal antibody was purchased from 
Cell Signaling Technology, Inc. and anti-GR mouse monoclonal antibody (BuGR2) 
was from Abcam, Ltd. Anti-GR rabbit polyclonal antibody was purchased from 
Affinity BioReagents, Inc. and ethanol was obtained from Arcus Kjemi AS. Precision 
Plus ProteinTM Standards Dual Color, PVDF membrane and Bio-Rad protein assay 
were purchased from Bio-Rad Laboratories, Inc. Sodium acetate was from Merck 
Chemicals Ltd. and geneticin sulphate (G418) was from Gibco, Invitrogen 
Corporation. DyNazymeTM II DNA Polymerase with its buffer was obtained from 
Finnzymes Oy and deoxyribonucleosine-5’-triphosphates (dNTPs) and 2-log DNA 
ladder were purchased from New England BioLabs, Inc. MatTek cultureware 35mm 
glass bottom microwell dishes were obtained from MatTek Corporation and 
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MycoAlert® Mycoplasma Detection Kit was from Lonza Biologics, Inc. 
Methyltrienolone (R1881) was purchased from DuPont NEN Research Products and 
primers were manufactured by Sigma-Genosys. 
3.2 Methods 
3.2.1 Cell lines and Cell culture 
The ell lines 3108 and 3617 are stably transfected derivates of the murine mammary 
adenocarcinoma cell line 3134 that contains 200 tandem repeats of a 9 kb element 
composed of the MMTV promoter followed by ras and BPV genes. These cell lines 
stably express GFP-tagged AR (3108) and GFP-tagged GR (3617),respectively, 
under the control of a tetracycline-off inducible system as previously described 
(McNally et al., 2000; Klokk et al., 2007). The passage number of both cell lines used 
in experiments was between 4 and 12. The cells were routinely maintained at 37ºC in 
a humidified 5% CO2 and 95% air incubator in DMEM supplemented with 10% fetal 
calf serum (FCS), 5mg/ml penicillin-streptomycin, 2mM L-glutamine and 10µg/ml 
tetracycline (to suppress GFP-AR and GFP-GR expression). The 3108 cell line was 
additionally supplemented with 1mg/ml G418 and 0.55 µg/ml puromycin. The 
culture medium was changed every second day. The MycoAlert® Mycoplasma 
Detection Kit was used to test cells for mycoplasma contamination. For the 
experiments cells were plated in culture medium without G418 and puromycin at a 
density of 3×105 (3108) and 2×105 (3617) cells per 10 cm dish and grown in the 
absence of tetracycline for induction of GFP-AR and GFP-GR, respectively, if not 
indicated differently. After reaching 30% confluence, cells were washed with 
phosphate-buffered saline (PBS) and serum starved for 2 days in medium containing 
10% charcoal treated (CT)-FCS to deplete the cells from steroids that could activate 
AR or GR. Prior to the experiments, cells were either left untreated or treated with 
TSA (100 nM) for 18 h, the synthetic androgen R1881 (10-8M) for 1 h or the 
synthetic glucocorticoid DEX (10-7M) for 30 min. 
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3.2.2 Protein extraction and Western analysis 
Cells grown and starved in the presence or absence of tetracycline were harvested by 
scraping in PBS and collected by centrifugation. Whole cell extracts were prepared 
by resuspending the cell pellets in 200 µl lysis buffer containing 20 mM HEPES (pH 
7.7), 300 mM NaCl, 0.2 mM EDTA, 0.1% Triton X-100, 1.5 mM MgCl2, 0.5 mM 
DTT, 20 mM β-glycerophosphate, 0.1 M Na3VO4, 2µg/ml leupeptin and 0.5 M 
PMSF. After rotating for 2 h at 4ºC, supernatants were collected by centrifugation at 
13,000 rpm for 20 min and the protein concentrations were determined by the Bio-
Rad protein assay. For western analysis, proteins (100µg) were separated on 8% 
SDS-PAGE gels. The Precision Plus ProteinTM Standards Dual Color was used as a 
molecular weight marker. Proteins were then transferred overnight to PVDF 
membranes activated in methanol. Blotted membranes were blocked in 5% nonfat dry 
milk in PBS containing 0.1% Tween for 1 h, followed by incubation overnight at 4ºC 
with primary antibodies diluted in PBS-Tween containing different amounts of 
bovine serum albumin (BSA). Antibodies used were rabbit polyclonal anti-AR 
antibody (N-20, Santa Cruz) diluted in 3% BSA (1:500), rabbit IgG fraction anti-GFP 
antibody diluted in 5% BSA (1:1000), mouse monoclonal anti-GR antibody (BuGR2, 
AbCam) diluted in 3% BSA (1:400), and mouse monoclonal anti-α-tubulin antibody 
diluted in 0.5% BSA (1:4000). Membranes were washed with PBS-Tween and 
incubated for 1.5 h at room temperature with secondary horseradish peroxidase HRP-
conjugated anti-rabbit (1:10000) or anti-mouse (1:5000) IgG antibodies diluted in 
PBS-Tween with 0.5% nonfat dry milk. All blots were visualized with the ECL 
Western Blotting Analysis System according to the manufacturer’s instructions. 
3.2.3 Live cell microscopy 
For live cell imaging, cells were plated at a density of 7×104 (3108) and 4×104 (3617) 
cells per MatTek dish. The cells were grown in medium without tetracycline and 
starved as described above. Prior to the microscopy experiments, cells were washed 
with PBS and the regular starving medium was replaced with phenol red-free 
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medium supplemented with 10% CT-FCS to eliminate autofluorescence. The cells 
were then treated with R1881 (10-8M) or DEX (10-7M) for indicated time periods or 
left untreated. Microscopy was performed with an Olympus FluoView 1000 confocal 
laser scanning microscope, equipped with an incubator maintained at 37ºC, and 
images were acquired with a 60x1.3 numerical aperture oil immersion objective and a 
488nm argon laser. 
3.2.4 Histone extraction and Western analysis 
Cells were plated, grown and starved under the same conditions as described 
previously. The cells were either left untreated or treated with R1881 (10-8M), DEX 
(10-7M), or TSA (100nM), alone or in combinations as indicated for the desired time 
periods. After washing with PBS, the cells were harvested by scraping in PBS and 
centrifugation. Harvested cells were washed twice with ice-cold PBS and 
resuspended in 500µl Triton extraction buffer (TEB) containing PBS with 0.5% 
Triton X-100, 2mM PMSF and 0.02% NaN3. PBS was supplemented with 5mM 
sodium butyrate to retain levels of histone acetylation. The cells were lysed on ice for 
10 min with gentle stirring followed by centrifugation at 2000 rpm for 10 min at 4ºC. 
After centrifugation, pelleted nuclei were washed in 250µl TEB and centrifuged as 
before. Nuclei were then resuspended in 150µl 0.2M HCl and lysed on a rotator at 
4ºC overnight. The supernatant containing histones were collected after 
centrifugation at 2000 rpm for 10 min at 4ºC and protein concentrations were 
determined using the Bio-Rad protein assay, followed by Western analysis. 10 µg 
aliquots of each sample together with the Precision Plus ProteinTM Standards Dual 
Color marker were resolved on 15% SDS-PAGE gels and transferred to methanol 
activated PVDF membranes overnight. Histone H3 and histone H4 acetylation were 
determined by blocking membranes in Tris-buffered saline (TBS) containing 0.1% 
Tween and 5% nonfat dry milk, and then probed with rabbit polyclonal anti-acetyl-
histone H3 antibody (1:10000 dilution) or anti-acetyl-histone H4 antibody (1:5000 
dilution) in TBS-Tween with 3% BSA overnight at 4ºC. Membranes were washed 
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and incubated for 1.5 h at room temperature with the secondary HRP-conjugated anti-
rabbit IgG antibody diluted in TBS-Tween with 0.5% nonfat milk (1:20000). Protein 
bands were visualized using Western Blotting Analysis System. To verify equal 
loading of samples, membranes were stripped with 0.5M NaOH followed by 
incubation in TBS-Tween with 5% nonfat dry milk and reprobed with rabbit 
polyclonal anti-histone H3 antibody diluted in TBS-Tween with 3% BSA (1:2000). 
Following secondary antibody application visualization was performed as described 
above. 
3.2.5 Chromatin Immunoprecipitation assay (ChIP) 
Cells were plated, starved and pretreated with TSA, R1881or DEX for indicated time 
periods as described above. Three independent experiments were carried out for each 
cell line. Following treatment with hormone, cells were cross-linked with 1% 
formaldehyde in culture medium at room temperature for 10 min. The fixing process 
was stopped by the addition of glycine to a final concentration of 0.125M and 
incubation at room temperature for 5 min. After washing with PBS, the cells were 
harvested by scraping in ice-cold PBS supplemented with 1x protease inhibitor 
cocktail and centrifugation. The cell pellet was resuspended in 300µl lysis buffer [1% 
SDS, 10mM EDTA, 50mM Tris-HCl pH8, 1x protease inhibitor cocktail] and 
sonicated using Biorupter UCD-200 (Diagenode). During sonication, samples were 
kept in ice-cold water and sonication was performed on high setting using 21 pulses 
of 7 sec each, with a 7 sec rest between each pulse (in total 5 min). Cell lysates were 
then centrifuged at 13,000 rpm at 4ºC for 10 min to pellet the insoluble material. 
Supernatants were collected and for determination of DNA concentration and 
shearing efficiency, 15µl aliquots were removed prior to dilution in dilution buffer 
[0.01% SDS, 1.1% Triton X-100, 1.2mM EDTA, 16.7mM Tris-HCl pH8, 1x protease 
inhibitor cocktail] to a total volume of 3ml followed by immunoprecipitation. 
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DNA concentration measurement 
4µl of each non-diluted sheared chromatin and 5µl proteinase K were added to 191µl 
lysis buffer supplemented with 40mM NaCl. The mixture was incubated at 65ºC for 1 
h and DNA concentration was measured with Biophotometer spectrophotometer 
(Eppendorf) at 260 and 280nm. 
Chromatin shearing  
5µl of each non-diluted sheared chromatin was added to a mixture containing 3µl 
proteinase K, 184 µl lysis buffer and 8µl 5M NaCl. The mixture was incubated at 
65ºC for 4 h or overnight and DNA was purified by extraction with phenol/chloro-
form, followed by addition of 0.1 volume of 3M sodium acetate and 2x volumes of 
ethanol and precipitation at -20ºC overnight. After 10 min centrifugation at 4ºC, the 
DNA pellet was washed once with 70% ethanol, dried and dissolved in 15µl double 
distilled water (ddH2O). The size of the sheared DNA was determined on a 1% 
agarose gel. Sheared chromatin runs as a smear in the size range of ~100-1500 base 
pairs, where the major fraction is at about 300-800 base pairs. 
Immunoprecipitation 
Equal amounts of diluted sheared chromatin was adjusted to the volume of 3ml with 
the dilution buffer and precleared on a rotator for 2 h at 4ºC with 200µl salmon sperm 
DNA/protein-A sepharose slurry (50% v/v beads in TE buffer supplemented with 
0.2mg salmon sperm DNA and 0.5mg BSA/ml) to avoid non-specific binding of 
protein-A sepharose. After preclearing, the beads were briefly centrifuged at 1000 
rpm at 4ºC for 1 min, the supernatants were collected and 1/10 of each sample was 
stored at 4ºC as an input control. The supernatant fractions were then subjected to 
chromatin immunoprecipitation overnight at 4ºC with 8 µg of either anti-acetyl 
histone H3 or H4 antibodies, 2µg anti-AR antibody (N-20, Santa Cruz) and 10µg 
anti-GR antibody (Affinity BioReagents). A control without any antibody was 
included for assessing non-specific binding. Following incubation with antibody, 
80µl of salmon sperm DNA/protein-A sepharose was added to each tube for 1 h with 
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rotation at 4ºC to isolate the immune complexes. The sepharose-antibody-chromatin 
complexes were then captured by centrifugation at 1000 rpm for 3 min at 4ºC and 
washed sequentially for 15 min (washes on a rotator platform, followed by 
centrifugation at 1000 rpm for 3 min), first in TSE I buffer [0.1% SDS, 1% Triton X-
100, 2mM EDTA, 20mM Tris-HCl pH8, 150mM NaCl], TSE II buffer [ TSE I with 
500mM NaCl], buffer III [0.25M LiCl, 1% NP-40, 1% sodium deoxycholate, 1mM 
EDTA, 10mM Tris-HCl pH8], and then in TE [10mM Tris-HCl pH8, 1mM EDTA]. 
All steps starting with the harvesting of the cells to the elution step were done in the 
presence of 5mM sodium butyrate. Sepharose bound proteins were then eluted twice 
with 250µl elution buffer [1% SDS in ddH2O] on a rotator at room temperature for 15 
min and eluates were combined. The stored input samples were eluted with 200µl 
elution buffer [ddH2O + 1% SDS in final solution]. Eluates were mixed with 20µl 5M 
NaCl, 10µl 0.5M EDTA, 20µl 1M Tris-HCl pH6.5 and 15.6 µg of proteinase K, and 
heated at 65ºC for at least 4 h to reverse the formaldehyde cross-linking between 
DNA and protein. DNA fragments were purified by phenol/chloroform extraction 
and precipitated with ethanol and 10µg carrier RNA (yeast tRNA) overnight at -20ºC. 
Following centrifugation, the DNA pellet was washed with 70% ethanol, dried and 
dissolved in 40µl ddH2O for further analysis by PCR. 
PCR analysis 
Following purification, the DNA was subjected to PCR amplification using primers 
specific for nucleosome B region of the MMTV promoter. The corresponding PCR 
product was 120 base pairs. Primers used were: forward 5`-TTTCCATACCAAG- 
GAGGGGACAGTG-3` and reverse 5`-CTTACTTAAGCCTTGGGAACCGCAA-3`. 
With all experiments, negative (no template-ddH2O) and positive (LTR plasmid) 
PCR controls were included. The PCR reaction was performed in a mixture (25µl), 
containing 2µl DNA, 10x reaction buffer, 0.4mM each of dATP, dTTP, dGTP and 
dCTP, 1.6mM MgCl2, 1 unit of DyNazyme II DNA polymerase, and 0.4µM of each 
primer. The reaction was carried out in a Peltier Thermal Cycler (PTC-200; MJ 
Research) using the following amplification conditions: 5 min denaturation at 95ºC 
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followed by 30 cycles of denaturation at 95ºC for 30 sec, annealing at 63ºC for 1min 
and extension at 72ºC for 1 min. In the end, there was a final extension for 5 min at 
72°C. The amplified DNA was analyzed on a 1.5% agarose gel. 
3.2.6 Quantitative PCR (qPCR) 
DNA isolated from precipitated chromatin was analysed by qPCR on a LightCycler® 
480 (Roche Diagnostics) using SYBR Green as a DNA-specific binding dye and 
continuous fluorescence monitoring. The PCR reaction (10µl) contained 2x SYBR 
Green I Master mix, 2µl of DNA template and 0.5µl of each primer. The primers, 
positive and negative controls used were same as described in conventional PCR 
analysis. The PCR program was comprised of an initial denaturating step at 95ºC for 
5 min followed by 45 cycles of denaturation (15sec at 95ºC), annealing (30sec at 
63ºC) and extension (20sec at 72ºC). To avoid non-specific PCR by-products and 
detect presence of possible primer dimers, melting curve was analysed: 5sec at 95ºC, 
1 min at 65ºC followed by continuous fluorescence measurement between 65ºC and 
97ºC. The crossing points (Cp) values calculated by the LightCycler computer 
software were used for determination of the initial amount of DNA template. 
Data analysis 
The data analysis was performed using Microsoft Office Excel 2003 software. The 
qPCR signals derived from the ChIP samples were normalized by the signals derived 
from the input samples. The level of acetylation in the absence of ligand and TSA 
treatment and the level of receptor enrichment in the absence of ligand were set to 1. 
The data presented represent the average of three independent experiments. Statistical 
analysis was performed using the Student’s two tailed t-test. Values of p < 0.05 were 
considered statistically significant. 
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4. Results 
4.1 Tetracycline-regulated expression of GFP-AR and GFP-GR 
In order to examine AR and GR mediated chromatin modifications of the MMTV 
promoter, the previously established 3108 and 3617 cell lines were used (McNally et 
al., 2000; Klokk et al., 2007). These cell lines contain an integrated tandem repeat of 
the MMTV promoter and express GFP-AR (3108) or GFP-GR (3617) in a stable and 
tetracycline repressible manner. Regulation of GFP-AR and GFP-GR expression in 
these cells by tetracycline was confirmed by Western analysis of total cell lysates, 
using antibodies against AR, GR and GFP. As can be seen in Figure 1, there was 
clear induction of GFP-AR (A) and GFP-GR (B) expression upon 72 h withdrawal of 
tetracycline from the medium, resulting in a band of expected size (~130 kDa). 
 
 









Figure 1. Tetracycline-regulated expression of GFP-AR and GFP-GR 
3108 (A) and 3617 (B) cells were grown and starved, as described in Materials and Methods, in the 
presence (+) or absence (-) of tetracycline (Tet). Whole cell extracts were prepared and subjected to 
Western analysis with antibodies specific to AR (A, upper-left panel), GR (B, upper-left panel) and 
GFP (A-B, upper-right panels). Tubulin was used as a loading control (A-B, lower panels). 
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4.2 Ligand-dependent translocation of GFP-AR and GFP-GR to   
the nucleus and their recruitment to the MMTV array  
The integrated MMTV array in the 3108 and 3617 cells contains approximately 800 
to 1000 HREs, which act as binding sites for both AR and GR. This has enabled the 
visualization of the GFP tagged AR and GR when bound to their response elements 
in living cells. Previously it was demonstrated that GFP-AR and GFP-GR within 
these cell lines translocate to the nucleus and bind to the array upon ligand activation 
(McNally et al., 2000; Klokk et al., 2007). We have also confirmed the effect of 
synthetic androgen R1881 (methyltrienolone) and synthetic glucocorticoid 
Dexamethasone (Dex) on intracellular translocation of GFP-AR and GFP-GR by live 











Figure 2. GFP-AR and GFP-GR translocate to the nucleus and bind to the MMTV 
array in response to their ligands 
Intracellular localization of GFP-AR (A) and GFP-GR (B) followed by in vivo time-lapse confocal 
microscopy at 37°C. (A) 3108 cells expressing GFP-AR were left untreated (a and c) or were treated 
with the synthetic androgen R1881 (10-8 M) for 30 min (b and d). GFP-AR was completely 
translocated to the nucleus after 30 min in response to R1881 (b) and recruited to the MMTV array 
(d). No translocation and binding to the array was observed in the absence of R1881 (a and c). (B) 
3617 cells expressing GFP-GR were treated with the synthetic glucocorticoid Dexamethasone (Dex) 
(10-7 M) for 30 min (b and d) or were left untreated (a and c). GFP-GR was completely translocated 
to the nucleus after 30 min in response to Dex (b) and recruited to the MMTV array (d). No 
translocation and binding to the array was observed in the absence of Dex (a and c). Arrows point the 
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Because the array in these cells exists as a unique, single amplified element on 
chromosome 4, a single bright GFP fluorescence signal was expected to be observed 
within the nucleus. In the absence of ligand, GFP-AR and GFP-GR were distributed 
predominantly in the cytoplasm and no significant binding to the MMTV array was 
observed (Figure 2Aa, 2Ac, 2Ba and 2Bc). The presence of agonists R1881 or Dex 
for 30 min caused complete translocation of AR or GR, respectively, to the nucleus 
(Figure 2Ab and 2Bb). Furthermore, a single bright fluorescent signal (Figure 2Ad 
and 2Bd), in addition to the diffuse nucleoplasmic GFP-AR and GFP-GR, was 
detected within the nucleus. These data confirm the intact nature of these cell lines as 
described in previous studies (McNally et al., 2000; Klokk et al., 2007). 
4.3 HDAC inhibitor TSA induces global histone acetylation 
independently of the presence of hormone 
HDAC inhibitors (HDACis) are generally used to manipulate the acetylation status of 
histones and to induce global histone hyperacetylation. Trichostatin A (TSA) is an 
efficient HDAC inhibitor (HDACi) and was shown to induce an increase in acetyl-
histone H3 levels in 3108 and 3617 cells in a time-dependent manner (Saatcioglu 
laboratory, unpublished data). To assess whether exposure of 3108 and 3617 cells to 
TSA treatment give rise to expected increase in histone H3 and H4 acetylation, cells 
were left untreated or were treated with 100 nM TSA for 18 h. Moreover, in order to 
examine if the TSA-induced histone acetylation was dependent on the presence of 
hormone, 3108 and 3617 cells were additionally treated with R1881 or Dex, 
respectively, alone or were pretreated with TSA prior to ligand addition. The histone 
extracts were obtained and subjected to Western analysis using antisera specific for 
acetyl-histone H3 and acetyl-histone H4 (Figure 3).  
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Figure 3. Acetylation of histone H3 and H4 in response to TSA and ligand activation 
3108 and 3617 cells were treated with TSA (100nM) for 18 h, or R1881 (10-8 M) for 1h or Dex (10-7 
M) for 30 min, alone or in combinations, or were left untreated. Histone extracts were obtained and 
subjected to Western analysis with antibodies specific to acetyl-histone H3 (A) or acetyl-histone H4 
(B). Anti-histone H3 antibody was used as a loading control (lower panels A and B). Molecular 
weight markers are indicated to the right of the figure. 
 
In the absence of TSA, both histones H3 (A) and H4 (B) exhibited low levels of 
acetylation that were strongly increased in response to TSA; total H3 levels were not 
affected. This confirmed the efficient inhibition of HDAC activity by TSA in 3108 
and 3617 cells. Furthermore, addition of R1881 or Dex did not alter the histone 
acetylation profiles generated by treatment with TSA alone. Thus, exposure to TSA 
results in global increase of histone acetylation patterns, independently of the 
presence of hormone. The acetyl-histone H4 antiserum also detected additional non-
specific band in 3108 cells at around 13 kDa (Figure 3B, left panel). This band shows 
similar response to TSA treatment as observed for acetylated histone H4 and might 
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could be a proteolytic fragment of histone H4 produced during extract preparation. 
However, the nature of this band was not investigated further.  
4.4 ChIP optimization  
Having established that the cell lines we wished to use in this study behaved as 
expected, we set out to use chromatin immunoprecipitation (ChIP) in these cells to 
probe dynamic changes of protein interactions at the MMTV array. ChIP is a 
powerful method used to identify regions of the genome associated with specific 
proteins, histone modifications, chromatin remodeling and other chromatin-related 
processes. In this study, the ChIP assay was used to study histone acetylation profiles 
at the Nuc-B region of the MMTV promoter in 3108 and 3617 cells. In addition, 
association of AR and GR with HREs of the MMTV promoter were also assessed by 
this method. The ChIP assays were carried out according to the standard protocol that 
was previously established in our laboratory, as described in Materials and Methods. 
However, after performing some preliminary ChIP assays to optimize it for use in 
these experiments, we lost all ChIP signal which was weak to start with; therefore, we 
needed to do several rounds of troubleshooting. 
To that end, the 3108 cells were left untreated or were treated with androgen R1881 
and subjected to the ChIP assay according to our standard protocol (Figure 4). 
Because the resolution obtained by the ChIP procedure depends on the size of 
chromatin fragments, it was first important to check if the shearing conditions used in 
the protocol resulted in the expected DNA smear in the desired size range 
(~200~1000 bp). As seen in Figure 4A, the major fraction of sheared DNA had 
optimal length of ~300~800 bp, similar to that detected by previous ChIP 
experiments performed in our laboratory (data not shown). Having established this, 
ChIP assay was processed to the end with the AR antibody which resulted in no ChIP 
based signal (Figure 4B).  
    MANUSCRIPT 













Figure 4. ChIP assay to assess AR binding to its HREs in the MMTV promoter using 
standard protocol conditions 
3108 cells were left untreated (-) or treated (+) with R1881 (10-8M) for 1 h and subjected to the ChIP 
assay using an antibody specific to AR, as described in Materials and Methods. The DNA molecular 
weight markers (M; in kb) are shown at the left of the figures. (A) Sheared DNA, (B) ChIP assay 
performed with AR antibody (2µg). No antibody (N.A.) was used as negative background control. 
Inputs represent the starting material before immunoprecipitation. Negative (N.c.) and positive (P.c.) 
are PCR performed in the absence of DNA containing the MMTV promoter, respectively. 
 
Since the PCR controls and inputs showed expected results, we reasoned that it may 
be the immunoprecipitation or the following steps that failed during the experiment. 
This could have been due to inefficient crosslinking, unsuccessful binding to the 
beads, incomplete/lack of elution or problems with the antibody. Thus, we first 
checked crosslinking conditions to assess if it was functional. Crosslinking is a time 
critical procedure, depending on the cell type and protein of interest. Excessive 
crosslinking can lead to decrease in the amount of protein bound to DNA and to 
reduction in the availability of epitopes for antibody binding, while too little 
crosslinking may not fix protein to its chromatin binding site. In the experiment 
presented above, crosslinking was carried out for 10 min at RT, but no signal was 
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help. As can be seen in Figure 5A, even longer crosslinking time did not improve the 
signal obtained in ChIP. In addition, crosslinking was also performed on ice for 20 









Figure 5. ChIP assay, optimization of crosslinking 
3108 cells were untreated (-) or treated (+) with androgen R1881 (10-8M) for 1 h and subjected to the 
ChIP assay using an antibody specific to AR, as described in Materials and Methods. The DNA 
molecular weight markers (M; in kb) are shown at the left of the figures. No antibody (N.A.) was 
used as negative background control. Inputs represent the starting material before 
immunoprecipitation. Negative (N.c.) and positive (P.c.) PCR controls are indicated. (A) ChIP assay 
with crosslinking time (CT) of 15 and 20 min at room temperature (RT). (B) ChIP assay with 
crosslinking time (CT) of 20 and 30 min on ice. 
 
Having shown that crosslinking was not a problem, the next step was to check if use 
of different antibodies specific for GFP-AR would improve the signal of precipitated 
samples. Antibodies are used to capture the DNA/protein complex and this step is 
typically the most critical one for a successful ChIP experiment. Thus, the antibody 
specific to AR (N-20, Santa Cruz) that was used in the experiments presented above 
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and an antibody specific to GFP (Invitrogen). However, neither of these antibodies 
resulted in a signal similar to experiments above (Figure 6A).  
Since varying the antibody did not help to solve the problem, we then turned to the 
Protein A Sepharose beads that are necessary for successful immunoprecipitation. In 
previous experiments we used Protein A Sepharose beads obtained from Invitrogen. 
To examine if there was something wrong with these beads, the next ChIP was 
performed with beads from a different supplier (GE-Healthcare) side by side with 
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Figure 6. Optimization of the ChIP assay with different antibodies and beads 
3108 cells were untreated (-) or treated (+) with androgen R1881 (10-8M) for 1 h and subjected to 
ChIP assay, as described in Materials and Methods. The DNA molecular weight markers (M; in kb) 
are shown at the left of the figures. No antibody (N.A.) was used as negative background control. 
Inputs represent the starting material before immunoprecipitation. Negative (N.c.) and positive (P.c.) 
PCR controls are indicated. (A) ChIP assay performed with antibodies specific to AR (Upstate) and 
GFP (Invitrogen). (B) ChIP assay performed with Protein A Sepharose (Invitrogen) and (GE-
Healthcare), and acetyl-histone H3 antibody. (C) ChIP assay performed with different amounts of 
AR (Santa Cruz) antibody, respectively 2, 4 and 6 µg. 
 
We used an antibody for acetyl-histone H3 which was previously shown to function 
well in ChIP (data not shown); since histones are far more abundant than chromatin 
bound AR, we expected to see a better signal if the ChIP failure was not due to a bead 
problem. As can be seen in Figure 6B, there is an expected signal only in samples 
that were processed with Protein A Sepharose obtained from GE-Healthcare. The 
Sepharose beads that were used in previous experiments resulted in a very weak band 
in the sample without hormone treatment (Figure 6B, lane 2). These results indicate 
that the failure of the ChIP assays presented previously was due to a problem with the 
Protein A Sepharose beads. 
As Protein A Sepharose beads were shown to be the cause of previous ChIP failures, 
we performed ChIP using new Protein A Sepharose beads and the AR antibody (used 
in Figure 4 and 5), (Figure 6C). In addition, a titration of the AR antibody was carried 
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antibody gave the best result, considering the ligand effect (lanes 2 and 3), compared 
to other concentrations that were used. With increasing amount of the antibody, there 
was a parallel increase in the background signal which diminished the ligand effect 
that was observed.  
Taken together, these results document that new Protein A Sepharose beads and the 
same amount of antibody as used in the standard protocol result in a proper ChIP 
signal. However, the signal is still weak and need further optimization, possibly by 
trying different antibodies and/or changing protocol conditions.  
4.5 Effect of TSA on histone acetylation at the MMTV promoter 
in the presence of AR 
Although TSA treatment induces an increase in global histone acetylation and 
modulates the activity of various promoters, it is often not clear whether there are 
changes in histone acetylation at specific target promoters. To investigate the effect 
of TSA on acetylation of histones at the MMTV promoter in response to AR 
activation, 3108 cells were either left untreated or treated with R1881, or TSA, alone 
or in combination, and ChIP assays were carried out with antibodies specific to the 
acetylated form of histone H3 and H4 (Figure 7). The MMTV promoter has six well 
defined positioned nucleosomes (Nuc) termed A-F (Richard-Foy and Hager, 1987). 
Nuc-B contains most of the HREs or and was subject of primary interest in this study 
(Figure 7A). To that end, the analysis of ChIP experiments was performed by PCR 
with primers specific to the Nuc-B region of the MMTV promoter. A representative 
analysis is shown in Figure 7B.  
There is a relatively high basal acetylation level of both histone H3 and H4 prior to 
treatment with R1881 and TSA (lanes 4 and 8). When the cells were treated with 
TSA alone, no change in acetylation of histone H3 (lane 6) and a moderate increase 
in acetylation of histone H4 (lane 10) was observed, compared to untreated cells. 
Surprisingly, androgen treatment reduced the basal acetylation level of histone H3 
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(lane 5), which further decreased in combination with TSA (lane 7). However, 
acetylation of histone H4 remained relatively unchanged upon hormone treatment, 
compared to that observed for untreated cells (lanes 9 and 11).  
The analysis of the ChIP experiments was also performed by quantitative PCR 
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Figure 7. Effect of TSA on acetylation of histone H3 and H4 at MMTV promoter 
nucleosome B in the presence and absence of R1881 
3108 cells were left untreated or were treated with R1881 (10-8M) for 1 h, treated with TSA (100nM) 
for 18 h, or pretreated with TSA (100nM) for 17 h followed by R1881 (10-8M) for 1 h. ChIP assays 
were performed as described in Materials and Methods, using antibodies against AR or acetylated 
histone H3 or H4. (A) A schematic presentation of the MMTV promoter. The approximate positions 
of the nucleosomes (A-F) as well as the binding sites for AR and basal transcription factors are 
indicated. The arrow shows the transcription start site. (B) A representative ChIP assay. Inputs 
represent the starting material before immunoprecipitation. No antibody (N.A.) was used as negative 
background control. Negative (N.c.) and positive (P.c.) PCR controls are indicated. The DNA 
molecular weight markers (M; in kb) are shown at the left of the figure. (C) The graph represents 
quantification of the real-time PCR results. ChIP signals determined by real-time PCR were 
normalized with the corresponding inputs and normalized-untreated samples were set to 1. Values 
mark the mean of three independent experiments with the error bars representing standard deviation. 
* means p < 0.05 as determined by Student’s t-test. 
 
The qPCR results showed a decrease in acetylation of histone H3 in the presence of 
androgen R1881, which is consistent with observations in Figure 7B. In fact, 
combination of hormone and TSA treatment resulted in a significant loss of histone 
H3 acetylation to about 50% of that seen in untreated cells. Furthermore, the presence 
of hormone appeared to decrease acetylation of histone H4, which increased when 
combined with TSA treatment. This does not correspond with the results observed in 
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and increased histone H4 acetylation which also differs from previous observations. 
Overall, these results indicate that acetylation of histone H3 in the Nuc-B region of 
the MMTV promoter is not increased by TSA under any treatment condition and is 
reduced upon R1881 treatment whereas there are no significant changes in 
acetylation of histone H4 under these conditions. 
In order to assess R1881-induced binding of AR with its binding sites at Nuc-B 
region of the MMTV promoter, ChIP experiments were also performed with antibody 
specific to AR. However, there was only a small increase in AR binding to HREs 
upon androgen activation observed, compared to untreated cells (Figure 7B, lanes 2 
and 3). In fact, qPCR analysis revealed that AR enrichment level in the presence of 
androgen is somewhat lower than that observed in untreated cells (Figure 7C). 
Furthermore, ChIP experiments showed a weak background signal in no antibody 
control, as expected (Figure 7B, lane 1). These results again indicate that the ChIP 
experiments for AR need to be optimized further. 
 
4.6 Effect of TSA on  histone acetylation at the MMTV promoter 
in the presence of GR  
The glucocorticoid receptor (GR), a member of steroid hormone receptor family, is 
closely related to the AR. Previously, it has been demonstrated that GR and AR bind 
in a similar dynamic manner to the same HREs of the MMTV promoter (McNally et 
al., 2000; Klokk et al., 2007). However, in response to HDACis, GR has been 
reported to possess a different behavior at the MMTV promoter compared with the 
AR. It was shown that, in contrast to AR, TSA inhibits GR transcriptional activity 
and does not affect the mobility of the agonist bound GR on the MMTV promoter 
(Mulholland et al., 2003; Saatcioglu lab, unpublished data). Therefore it became of 
interest to investigate the effect of TSA on acetylation of histones at the MMTV 
promoter in response to GR activation. ChIP assays were performed with antibodies 
specific to the acetylated form of histone H3 and H4 in 3617 cells in the presence or 
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absence of Dex/TSA (Figure 8). As GR binds to the same HREs of the MMTV 
promoter as AR (see Figure 7A), Nuc-B contains most of the GR-binding sites. The 
analysis of ChIP experiments were carried out by PCR with primers specific to the 
Nuc-B region of the MMTV promoter similar to AR. A representative analysis is 
shown in Figure 8A. There was an expected increase in GR binding to HREs upon 
Dex activation compared to untreated cells (lanes 2 and 3). This was consistent with 
the results obtained by qPCR analysis. There was high level of basal acetylation of 
both histone H3 and H4 prior to treatment with Dex and TSA (lanes 4 and 8), similar 
to that observed in 3108 cells for AR. Furthermore, histone H3 showed relatively 
similar acetylation levels under all treatment conditions that were lower than basal 
acetylation (lanes 5-7). However, acetylation of histone H4 remained relatively 
unchanged upon hormone and TSA treatment alone, compared to untreated cells  
(lanes 9 and 10), with a small increase observed upon combination of these two 
treatments (lane 11).  
The analysis of the ChIP experiments was also performed by qPCR and a graphic 
summary is shown in Figure 8B. The graph presented in Figure 8B represents results 
obtained from one single ChIP experiment; additional experiments are in progress. 
The qPCR results showed a small decrease in acetylation of histone H3 in the 
presence of Dex alone and in combination with TSA, which is consistent with 
observations in Figure 8B. Additionally, acetylation of histone H4 was decreased in 
the presence of TSA alone and in combination with Dex, and increased upon 
hormone treatment. These results do not correspond with results observed in Figure 
8B that show relatively unchanged levels of histone H4 acetylation, which indicates 
the need for additional experiments.   
Taken together, TSA treatment does not appear to increase acetylation levels of 
histone H3 and H4 in the Nuc-B region of the MMTV promoter of 3617 cells and it 
does not seem to be reduction in H3 acetylation upon Dex treatment. Thus, there may 
be differences between AR- and GR-mediated changes in histone acetylation at the 
MMTV promoter.  
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Figure 8. Effect of TSA on acetylation of histone H3 and H4 at MMTV promoter nucleosome B 
in the presence and absence of Dex 
3617 cells were treated with Dex (10-7M) for 30 min or TSA (100nM) for 18 h, alone or in 
combination or were left untreated. ChIP assays were performed as described in Materials and 
Methods, using antibodies against GR or acetylated histone H3 or H4. (A) A representative analysis 
of ChIP assay. Inputs represent the starting material before immunoprecipitation. No antibody (N.A.) 
was used as negative background control. Negative (N.c.) and positive (P.c.) PCR controls are 
indicated. The DNA molecular weight markers (M; in kb) are shown at the left of the figure. (B) The 
graph represents quantification of the real-time PCR results. ChIP signals determined by real-time 
PCR were normalized with the corresponding inputs and normalized-untreated samples were set to 1. 
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5. Discussion and Future Perspectives 
Histone acetylation represents an important mechanism in the regulation of gene 
activity. Acetylation is generally associated with increased gene transcription whereas 
deacetylation is linked to transcriptional repression (Ng and Bird, 2000; Berger, 
2002; Verdone et al., 2005). However, a number of studies suggest a more complex 
scenario with respect to individual genes and/or promoters (Deckert and Struhl, 2001; 
Mulholland et al., 2003) and the underlying mechanisms are not fully understood. 
Previous work in our laboratory demonstrated the consequences of changes in histone 
acetylation induced by the HDAC inhibitor TSA on dynamics and transcriptional 
activity mediated by AR and GR at the MMTV promoter (unpublished data). While 
TSA reduced AR mobility that correlated with an increase in transcriptional activity, 
the mobility and transcriptional activity of GR was not affected by TSA. These 
observations were consistent with previous investigations that reported differential 
response of AR and GR to TSA at the MMTV promoter (List et al., 1999; 
Mulholland et al., 2003).  
In this study, the acetylation status of the MMTV promoter in response to the HDAC 
inhibitor TSA in the presence of AR and GR was examined with the aim to get clues 
as to why these two receptors respond differently to TSA. The data presented indicate 
that there are some differences in acetylation levels of histone H3 at the MMTV 
promoter in response to TSA in the presence of AR, but not GR (Figure 7B and 8A). 
The treatment with AR-agonist R1881, independent of the presence of TSA, resulted 
in a decrease in histone H3 acetylation at Nuc-B within the MMTV promoter (Figure 
7B, lane 5), which was further decreased after TSA treatment (Figure 7B, lane 7). 
These observations indicate an unexpected negative correlation between MMTV 
transcriptional activation by AR reported previously (List et al., 1999; Klokk et al., 
2007), and histone acetylation at the MMTV promoter. These data suggest that the 
increased transcriptional activity of AR at the MMTV promoter in response to TSA is 
associated with another mechanism than increased histone acetylation. Results 
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obtained from preliminary studies of the MMTV promoter in the presence of GR 
suggest a different pattern of histone H3 acetylation compared to AR (Figure 8B). 
The acetylation level of histone H3 is relatively unchanged after treatment with the 
synthetic glucocorticoid Dex alone or in combination with TSA; this is correlated 
with no effect of TSA on GR transcriptional activity at the MMTV promoter. 
However, it should be pointed out that additional studies, including replication of the 
experiments presented here, are needed in order to draw final conclusions regarding 
the details of histone acetylation during AR- and GR-mediated transcriptional 
activation at the MMTV promoter in response to TSA. The variations that we 
experienced in the different ChIP experiments could be due to variations between 
batches of antibody, the chromatin preparation, or differences in the efficiency of the 
actual immunoprecipitation process for a given antibody; further work is in progress 
to check these possibilities. 
We found that in any of the ChIP analyses of histone H3 or H4 at Nuc-B of MMTV 
promoter, under any treatment conditions, there was no increased acetylation (Figure 
7B and 8A, lanes 6, 7, 10 and 11). Thus, even though TSA treatment induced global 
histone hyperacetylation (Figure 3A and 3B), the MMTV promoter, at least the Nuc-
B region, was unaffected. Together, these results suggest that the primary target of 
HDAC inhibition by TSA at the MMTV promoter may be a non-histone coregulatory 
protein that is involved in an essential step of AR- or GR-mediated transcription 
rather than core histones. Alternatively, dynamic acetylation and deacetylation of 
specific residues of histone H3 and H4 may be occurring that cannot be detected in a 
global search for changes. 
Potential non-histone targets of TSA could be HDACs, which have shown to possess 
both activation and repression properties as coregulators of nuclear receptors (for a 
review, see Gallinari et al., 2007). For instance, if TSA inhibited the repressive 
function of an AR-associated HDAC and activation action of a GR-associated 
HDAC, it could potentially explain opposite effect of the same compound. HDAC1 is 
indeed sensitive to inhibition by TSA (Marks et al., 2001) and have a distinct role in 
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transactivation by AR and GR (Shang et al., 2002; Qiu et al., 2006). While HDAC1 
had an inhibitory effect on AR activity on the PSA promoter, suggesting that it acts 
as a corepressor for AR (Shang et al., 2002), it was shown to serve as a coactivator 
for GR-mediated activation of the MMTV promoter (Qiu et al., 2006). Interestingly, 
the coactivator activity of HDAC1 was shown to be regulated by acetylation that 
suppresses its deacetylase activity, allowing GR-induced transcription (Qiu et al., 
2006). It would therefore be of interest to study the acetylation status of HDAC1 and 
its association with both receptors under the conditions used in this study. 
AR and GR are also subject to posttranslational modifications that play a role in 
modulation of their transcriptional activities (reviewed in Faus and Haendler, 2006). 
Among these, both AR and GR have acetylation motifs (KxKK) within their DBD-
hinge domains (Fu et al., 2000; Ito et al., 2006). Hormone dependent activation of 
AR was shown to be dependent on acetylation of three lysine residues in this region 
by coactivators that harbour HAT activity and modulate AR transcriptional activity 
by favouring nuclear translocation and altering its association with coactivators and 
corepressors (Fu et al., 2000; Fu et al., 2002; Gaughan et al., 2002). GR, similar to 
AR, is also acetylated at this motif upon hormone activation, although this does not 
seem to affect its transcriptional activity (Ito et al., 2006). Thus, TSA treatment may 
inhibit HDACs that deacetylate both AR and GR, resulting in increased acetylation 
that would possibly increase AR activity without effecting function of GR. Indeed, 
earlier studies have demonstrated that TSA treatment results in increased acetylation, 
and thereby increased activity, of AR (Fu et al., 2000; Fu et al., 2003). Even though 
AR acetylation may explain its increased activity in response to HDAC inhibition, 
there is also a possibility of other modifications or cross-talk between the 
modifications being involved. For example, AR is also known to be a phosphoprotein 
(Gioeli et al., 2002); there could potentially be interactions between acetylation and 
phosphorylation events that determine AR activity. Exploring the acetylation status of 
AR/GR and use of acetylation mutants may further reveal if the different responses of 
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AR and GR to TSA are connected to their posttranslational modification by 
acetylation. 
An alternative explanation of the current results is that inhibition of HDAC activity 
could lead to increased acetylation of a member of the transcription initiation 
complex, such as general transcription factors or coactivators that could account for 
increased/decreased transcriptional activity. In fact several coactivators that interact 
with the basal transcription machinery, including PCAF, p300, and SRC1 are known 
to be acetylated (Chen et al., 1999; Sterner and Berger, 2000) and these act as 
cofactors for AR and GR (for reviews, see Jenkins et al., 2001; Heinlein and Chang, 
2002). However, the effect of acetylation on the function of these proteins is currently 
unknown. Alternatively, it is possible that an HDAC involved in GR-mediated 
transcription would be insensitive to TSA treatment, resulting in a different response 
than with AR. 
It is important to note that in the studies described in this thesis, the cells were 
exposed to TSA for relatively long periods of time (18 hours). During this time 
period, some secondary effects of HDAC inhibition could occur, such as changes in 
expression levels of AR or GR, or their coregulatory proteins. Recent data from our 
laboratory indicate that there is an increase in expression of both AR and GR in 
response to TSA (unpublished data). However, it is not clear whether these changes 
alone can account for the transcriptional effects observed. In addition, expression 
levels of HDAC1 in response to TSA and corresponding ligands were also examined 
by Western analysis and immunostaining. The results showed no change in 
expression levels of HDAC1 in the presence of TSA and androgen or glucocorticoid 
(Saatcioglu laboratory, unpublished results). Thus, different effect of TSA on AR- 
and GR-mediated transcription is most probably not connected to differences in 
expression levels of the receptors or HDAC1. 
Overall, although ChIP analyses indicate differences in the acetylation profile of the 
MMTV promoter in the presence of AR compared to GR in response to TSA, these 
do not seem to directly correlate with AR and GR transcriptional activity, suggesting 
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a more complex mechanism of transcriptional regulation. It is possible that increased 
acetylation of non-histone proteins may have equal or greater importance in 
mediating effects of TSA. However, as pointed out above, more direct and significant 
changes in the acetylation status of selected sites on histones may occur which could 
be critical for the observed differences between AR and GR. Further work is required 
to examine these possibilities. 
Finally, it should be emphasized that although ChIP analysis is a powerful method 
used to examine chromatin-related processes and was the primary method used in this 
study, additional optimization is required for some of the experiments. For example, 
although ChIP conditions were extensively optimized prior to the experiments, only a 
small difference could be observed in the enrichment of AR on the MMTV promoter 
in response to androgen. We now know that this is due to the limitation of the AR 
antibody that we used, as most recent studies using GFP antibody reproducibly give 
significant enrichment of MMTV-bound AR in response to hormone (Saatcioglu 
laboratory, unpublished results). Thus, some of the experiments presented in this 
thesis need to be repeated for conclusive results. 
In order to determine what accounts for differential responses of AR and GR to TSA 
on the MMTV promoter, it is important to identify the exact factors that are used in 
transcriptional activation by the two receptors in this context. For example, it is of 
interest to determine which HDACs are involved with each receptor and how they 
affect their transactivation potential on the MMTV promoter. As briefly discussed 
above, one obvious candidate in this regard is HDAC1 whose possible contributions 
could be checked through overexpression and/or knock-down experiments. 
Furthermore, it may be essential to examine the acetylation status of other 
nucleosomes at the MMTV promoter upon hormone and TSA treatment, and also 
investigate the acetylation status of specific residues within each histone. In addition, 
the investigation of AR acetylation mutants would conclusively assess whether AR 
acetylation is involved in its response to TSA. These and other studies will shed light 
on the details of AR/GR-chromatin interplay at the MMTV promoter. 
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